 Version 6.0 
September 11 , 2017  
 
RESOLVE  Protocol  
 
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir , and Voxilaprevir  
in Subjects with previous DAA experience  
 
Sponsored by  
[INVESTIGATOR_646222], University of Maryland School of Medicine  
Baltimore, MD  
And  
[COMPANY_009] Sciences, Inc.  
Foster City, [LOCATION_004]  
 
IND Number  
128754  
 
IND sponsored by  
[INVESTIGATOR_646222], University of Maryland School of Medicine  
Baltimore, MD 
 
Medical Monitor  
Theo Heller, MD  
 
 
 
 
 
 
 
 
 
Principal Investigator:  
[INVESTIGATOR_762351], MD, MHS  
Assistant Professor of Medicine  
Institute of Human Virology  
University of Maryland School of Medicine  
[ADDRESS_1044329], Room S218  
Baltimore MD [ZIP_CODE]  
Phone: (410) 706 -1710  
 
IRB Initial Approval :   February 22, 2016  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044330] INFORMATION  
 
Principal Investigator : 
[INVESTIGATOR_762351], MD, MHS  
Assistant Professor of Medicine  
Institute of Human Virology  
University of Maryland School of Medicine  
[ADDRESS_1044331], Room S218  
Baltimore MD [ZIP_CODE]  
Phone: (410) 706 -1710  
[EMAIL_14561]  
 
Research contact/Study Coordinator:  
Jennifer Hoffman n, MSN, MPH  
 
Associate Investigators : 
Elizabeth Akoth, RN  
Benjamin Emmanuel, MPH  
Emily Comstock, MSN, CRNP  
Emily Covert, BS  
Janet Gripshover, MSN, CRNP  
Chloe Gross, RN  
Jennifer Hoffmann, MSN, MPH  
Sarah Kattakuzhy, MD  
Mariam Khambaty , MD  
Shyam Kottilil, MD PhD 
Poonam Mathur, MD  
Lydiah Mutumbi, RN  
Amy Nelson, RN  
Angie Price, MSN, CRNP  
Elana Rosenthal, MD  
Rachel Silk, RN, MPH  
Lydia Tang, MD  
Haley Ward, BS  
 
Study Site s: 
Institute for Human Virology, University of 
Maryland School of Medicine, Baltimore, MD  
Unity  Health C are Parkside and Walker -Jones ,  
Washington, DC  
 
Pharmacy:  
Lisa Langer, RPh  
Christina Dickson, RPh  
  
Protocol Statistician : 
Søren Bentzen , Ph.D.,  
Biostatistics Research Branch  
University of Maryland  
 
 
Collaborating Investigators : 
Gebeyehu Teferi, MD, Unity Health Care  
 
Collaborating Institutions:  
 
Unity Health Care, Inc./Walker Jones  
Site AI: Gebeyehu Teferi, MD  
FWA: 00009653, expi[INVESTIGATOR_320] 6/19/[ADDRESS_1044332], NE  
Washington, DC [ZIP_CODE]  
Phone: (202) 354 -1150  
FAX: ([PHONE_15931]  
E-mail:   [EMAIL_14562]  
 
Unity Health Care, Inc. /Parkside  
Site AI: Gebeyehu Teferi, MD  
FWA: 00009653, expi[INVESTIGATOR_320] 6/19/2018  
765 Kenniworth Terrace,  NE 
Washington, DC [ZIP_CODE]  
Phone: ([PHONE_15932]  
FAX: ([PHONE_15933]  
E-mail:   [EMAIL_14562]  
 
 
IND Sponsor:  Institute of Human Virology  
 
Medical Monitor:  
Theo Heller, MD  
 
IRB of Record:  
University of Maryland, Human Research 
Protections Office, Institutional Review Board  
[ADDRESS_1044333] , Second Floor  
Baltimore, Maryland [ZIP_CODE]  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044334] INFORMATION  ................................ ............................  2 
ABBREVIATIONS  ................................ ................................ ................................ .......................  6 
ABBREVIATIONS FO R HCV STUDY AGENTS & FDA  APPROVED AGENTS  .............  9 
PRÉCIS  ................................ ................................ ................................ ................................ ........  10 
STUDY SUMMARY  ................................ ................................ ................................ ...................  11 
STUDY SCHEMA  ................................ ................................ ................................ ......................  13 
1 INTRODUCTION AND RAT IONALE  ................................ ................................ ........  14 
1.1 Chronic Hepatitis C Infection: Background  ................................ ................................ ..... 14 
1.2 Rationale for New Combination DAA Therapi[INVESTIGATOR_014]  ................................ .............................  14 
1.3 RATIONALE FOR SELECTION OF ALLOWED CONCOMITANT ARV REGIMENS
 15 
1.4 SOFOSBUVIR  ................................ ................................ ................................ ..................  15 
1.5 SOF/VEL  ................................ ................................ ................................ ..........................  15 
1.6 SOF/VEL/VOX ................................ ................................ ................................ .................  16 
1.6.1  Voxilaprevir  ................................ ................................ ................................ ..........  16 
1.6.2  Summary of Clinical Experience with SOF/VEL/VOX  ................................ .........  16 
1.6.3  FDA -approval  ................................ ................................ ................................ ....... 16 
1.6.4  Phase 3 Studies with Vosevi  ................................ ................................ ........................  16 
1.7 Pharmacokinetics of SOF/VEL/VOX  ................................ ................................ ...............  17 
1.8 Safety of SOF/VEL/VOX  ................................ ................................ ................................ . 17 
1.9 Rationale for Dose Selection of SOF/VEL/VOX  ................................ .............................  17 
1.10  Overall Risk/Benefit Assessment  ................................ ................................ .....................  18 
2 STUDY DESIGN A ND METHODS ................................ ................................ ..............  18 
2.1 Primary Objective  ................................ ................................ ................................ .............  19 
2.2 Secondary Objectives ................................ ................................ ................................ ........  19 
2.3 Exploratory Objectives  ................................ ................................ ................................ ..... 19 
2.3.1  Rationale for Immunologic studies  ................................ ................................ ....... 19 
2.4 Study Population  ................................ ................................ ................................ ...............  21 
2.4.1  Inclusion Criteria  ................................ ................................ ................................ .. 21 
2.4.2  Exclusion Criteria  ................................ ................................ ................................ . 24 
2.5 Pharmacokinetic and Viral Kinetic Substudy  ................................ ................................ ... 25 
2.6 Recruitment Plan  ................................ ................................ ................................ ...............  25 
2.7 Human Subjects Protections  ................................ ................................ .............................  25 
2.7.1  Gender, Ethnicity, and Race Considerations  ................................ ........................  26 
2.7.2  Rationale for the Exclusion of Childre n and Pregnant Women  ...........................  26 
2.7.3  Contraception  ................................ ................................ ................................ ....... 26 
2.8 Clinical Procedures and Schedule of Evaluations  ................................ ............................  26 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 4 of 55 
 2.8.1  Screening ................................ ................................ ................................ ...............  27 
2.9 Randomization and Blinding  ................................ ................................ ............................  28 
2.10  History and Physical  ................................ ................................ ................................ .........  28 
2.11  Starting SOF/VEL/VOX (Day 0) ................................ ................................ ......................  29 
2.12  Optional PK/VK Substudy  ................................ ................................ ................................  29 
2.13  Week 1 Visit  ................................ ................................ ................................ .....................  29 
2.14  Week 2 Visit  ................................ ................................ ................................ .....................  29 
2.15  Week 4 Visit  ................................ ................................ ................................ .....................  29 
2.16  Week 8 Visit  ................................ ................................ ................................ .....................  29 
2.17  Week 12 / End of Treatment Visit  ................................ ................................ ....................  [ADDRESS_1044335] Values  ................................ ..................  30 
2.20.2  Criteria for Premature Withdrawal and Stoppi[INVESTIGATOR_1869]  ................................ ...... 31 
3 STUDY AGENTS ................................ ................................ ................................ ............  31 
3.1 Disposition and Dispensation  ................................ ................................ ...........................  31 
3.2 Packaging and Labeling of Study Drugs  ................................ ................................ ..........  31 
3.2.1  Formulation  ................................ ................................ ................................ ..........  32 
3.2.2  Packaging and Labeling  ................................ ................................ .......................  32 
3.2.3  Storage and Handling  ................................ ................................ ...........................  32 
3.3 Treatment of Subjects  ................................ ................................ ................................ ....... 32 
3.4 Dose Modifications / Toxicities  ................................ ................................ ........................  32 
3.4.1  Dose Modification for SOF/VEL/VOX ................................ ................................ .. 33 
3.4.2  Treatment Failure / Drug Discontinuation  ................................ ...........................  33 
3.4.3  Treatment Failure Criteria After Stoppi[INVESTIGATOR_199599]/VEL/VOX  ................................ . 33 
3.4.4  Viral Co -infection Rebound Schema  ................................ ................................ ..... 34 
3.5 Concomitant Medications  ................................ ................................ ................................ . 34 
4 STATISTICAL CONSIDER ATIONS  ................................ ................................ ..........  36 
4.1 Sample Size  ................................ ................................ ................................ .......................  36 
4.1.1  Primary Endpoint ................................ ................................ ................................ .. 37 
4.1.2  Secondary Endpoints  ................................ ................................ ............................  38 
4.1.3  Safety Endpoints ................................ ................................ ................................ .... 38 
4.1.4  Analysis Sets ................................ ................................ ................................ ..........  38 
4.2 Data  Handling Conventions  ................................ ................................ ..............................  39 
4.3 Demographic Data and Baseline Characteristics  ................................ ..............................  39 
4.4 Adverse Events  ................................ ................................ ................................ .................  39 
5 STUDY TE STS................................ ................................ ................................ ................  40 
5.1 Schedule of Tests  ................................ ................................ ................................ ..............  40 
6 HAZARDS/DISCOMFORTS/ RISKS  ................................ ................................ ...........  44 
6.1 Drugs  ................................ ................................ ................................ ................................ . 44 
6.1.1  Sofosbuvir  ................................ ................................ ................................ .............  44 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 5 of 55 
 6.1.2  Velpatasvir  ................................ ................................ ................................ ............  44 
6.1.3  Voxilaprevir  ................................ ................................ ................................ ..........  45 
6.1.4  Resistance  ................................ ................................ ................................ .............  45 
6.2 Procedures  ................................ ................................ ................................ .........................  45 
6.2.1  Phlebotomy  ................................ ................................ ................................ ...........  45 
6.2.2  Electrocardiogram  ................................ ................................ ................................  45 
6.2.3  Liver Biopsy  ................................ ................................ ................................ ..........  45 
7 BENEFITS/COMPENSATIO N/ALTERNATIVES  ................................ ....................  [ADDRESS_1044336] retention  ................................ ................................ ................................ ....... 53 
10 REFERENCES  ................................ ................................ ................................ ................  54 
 
  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044337] acting antiretroviral  
DDI Drug -drug interaction  
DNA  Deoxyribonucleic acid  
DRV  Darun avir 
EBR  Elbasvir  
ECG  Electrocardiogram  
ELISA  Enzyme -linked immunosorbent assay  
ESAs  Erythropoiesis stimulating agents  
ETR  End of Treatment Response  
EVG  Elvitegravir  
FDA  Food and Drug Administration  
FDC  Fixed dose combination  
GCP  Good Clinical Practices  
GCSF  Granulocyte colony stimulating factor  
GS [COMPANY_009] Sciences, Inc.  
GT-1, -2, and -3 Genotype  1,2, and 3  
GZR  Grazoprevir  
HbA1c  Hemaglobin A1C  
HBV  Hepatitis B virus  
HBsAg  Hepatitis B surface antigen  
hCG  Human chorionic gonadotropin  
HCV Hepatitis C virus  
HIV Human immunodeficiency virus  
HLA  Human leukocyte antigen  
IB Investigator’s Brochure  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044338]  
ISR Interferon sensitive gene  
LDV  Ledipasvir  
LIL Liver infiltrating lymphocytes  
MM Medical Monitor  
NS3/4  Non-structural proteins 3 and 4, protease  
NS5A  Non-structural protein 5A  
NS5B  Non-structural protein 5B, polymerase  
NSAID  Nonsteroidal anti -inflammatory drug  
PBMC  peripheral blood mononuclear cells  
PD Pharmacodynamics  
PI [INVESTIGATOR_762352] (co -dosed with ritonavir [paritaprevir/r]), ombitasvir, 
dasabuvir  
RAL  Raltegravir  
RAV  Resistance Associated Variants  
RBV  Ribavirin  
r  Ritoni vir 
RPV Rilpi[INVESTIGATOR_762353] 4 HCV RNA < LLOQ 4  weeks after completion of treatment  
SVR 8 HCV RNA < LLOQ 8  weeks after completion of treatment  
SVR 12 HCV  RNA < LLOQ 12 weeks after completion of treatment  
SVR 24 Sustained virologic response <LLOQ HCV RNA 24 weeks (or 6 
months) after the end of treatment  
TPO  Thrombopoeitin  
ULN  Upper limit of normal  
UP Unanticipated problem  
UPnonAE  Unanticipated problem that is not an adverse event  
VEL  Velpatasvir  
VK Viral kinetics  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 8 of 55 
 VOX  Voxilaprevir  
WBC  White blood cell  
 
  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 9 of 55 
 ABBREVIATIONS FOR H CV STUDY AGENTS & FDA  APPROVED AGENTS  
 
GS-7977, SOF  Sofosbuvir, nucleotide NS5B inhibitor , an FDA approved treatment for 
HCV  
GS-5816 , VEL  Velpatasvir, s econd generation NS5A inhibitor , an HCV study agent  
GS-9857 , VOX  Voxilaprevir, s econd generation NS3/4A protease inhibitor, an HCV study agent  
SOF/VEL /VOX  
FDC , Vosevi  Fixed dose combination of sofosbuvir, an FDA -approved NS -5B nucleotide 
inhibitor, 400mg ; velpatasvir , an FDA -approved NS5A inhibitor, 100mg ; and 
GS-9857, a second generation FDA -approved  NS3/4A protease inhibitor, 300 mg  
IFN, PegIFN, 
PEG  Interferon (known as pegylated IFN or pegIFN)  
RBV  Ribavirin, an FDA approved standard of care treatment for HCV when  
used with Interferon and/or an additional agent  
Viekira Pak , 
PrOD  Ombitasvir, paritaprevir (co -dosed with ritonavir [paritaprevir/r]), 
dasabuvir   
  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 10 of 55 
  
PRÉCIS  
Chronic hepatitis C virus (HCV) infection is a major public health problem with an estimated 
180 million people infected worldwide. In the [LOCATION_002], an estimated 4.1 million people 
are infected, and HCV is the principal cause of death from liver disea se and leading indication 
for liver transplantation. While treatment with combination directly acting antiviral agents 
(DAAs) represents a dramatic improvement over previous therapi[INVESTIGATOR_762354], tolerability and 
efficacy, these therapi[INVESTIGATOR_762355] y effective and some patients fail to achieve sustained 
virologic response (SVR).  As DAA medications become more widely available outside clinical 
trial settings, it is important to evaluate retreatment strategies in patients who fail combination 
DAA ther apy.  As of yet, t he ideal retreatment strategy and predictors of response in these 
patients have not yet been determined.  In this trial, we will test the safety, tolerability, and 
efficacy of treatment with sofosbuvir (an approved NS5B inhibitor), velpat asvir (formerly GS-
5816 , a second generation NS5A inhibitor) and voxilaprevir (formerly GS-9857 , an NS3/4A 
protease inhibitor)  (trade name [CONTACT_526728])  in HCV infected patients with early and advanced liver 
disease , including those coinfected with HIV  and or hepatitis B , who have failed previous 
combination DAA therapi[INVESTIGATOR_014]. The findings from this study will aid in our understanding of 
determinants of response to combination DAA regimens in HCV infected patients for 
subgroups of patients with early as com pared to advanced liver disease, in patients with HCV 
GT 1 subtypes a and b, in patients coinfected with HIV and or hepatitis B , and in patients 
previously failing different combination DAA therapi[INVESTIGATOR_014] . 
 
  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 11 of 55 
 STUDY SUMMARY  
 
Title : Safety, Tolerability and Effica cy of Sofosbuvir, Velpatasvir  and Voxilaprevir  in 
Subjects w ho failed  previous DAA Therapy  
Short Title:  RESOLVE Protocol  
Clinical Phase:  Phase II b 
 
IND Sponsor:   IHV/University of Maryland SOM  
 
Principal  
Investigator:   [INVESTIGATOR_762351] , MD, MHS  
 
Sample Size:  N=120 
 N=20 participants in a pharmacokinetic/viral kinetic sub study  
      10 with and 10 without cirrhosis  
 
Accrual Ceiling:  N=150 
 
Study Population:  HCV , genotype 1,  infected subjects , with or without HIV,  who have previously 
been treated with unsuccessful combination DAA -based therapy  
 
Accrual Period:   1 year  
 
Study Design:  Open-label phase II b study to examine safety, tolerability , and efficacy of 
SOF/ VEL /VOX  in subjects with chronic HCV infection who have failed to 
eradicate HCV despi[INVESTIGATOR_762356]. Subjects with cirrhosis  
and those without cirrhosis will receive 12 weeks of therapy  and will be  stratified 
by [CONTACT_762382] . 
Study  
Agents : SOF/ VEL /VOX  is a fixed dose combination of sofosbuvir, an FDA -approved NS -
5B nucleotide inhibitor, 400mg ; velpatasvir , an FDA -approved  NS5A inhibitor, 
100mg; and voxilapravir , an FDA approved  NS3/4A protease inhibitor, 1 00 mg, 
dosed once d aily.  
Treatment  
Duration : Subjects with and without cirrhosis will receive 12 weeks of therapy   
 
Primary  
Objectives : To assess the safety, tolerability, and efficacy of 12 weeks of SOF/ VEL /VOX  in 
subjects with chronic HCV infection who have previously failed FDA approved 
DAA -based  therapy , with compensated cirrhosis  and without cirrhosis , with and 
without HIV coinfection.  
 
Secondary  
Objectives : 1. To evaluate the immunologic, virologic, and host genetic/proteomic predictors of 
response to therapy with S OF/VEL /VOX  in HCV infected subjects who have failed 
previous combination DAA -based therapy . 
 
 2. To compare HCV quasispecies and resistance associated variants (RAVs)  at 
baseline and throughout treatment, especially in the case of relapse or 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044339] of SOF/ VEL /VOX  on peripheral markers of T cell 
activation  
 5. To evaluate the proportion of subjects whose alanine aminotransferase (ALT) 
levels normalize between baseline and SVR 4,12,[ADDRESS_1044340] immune 
recovery in patients receiving single (SPARE), or combination D AA-based  therapy 
(RESOLVE ). 
 
Primary  
Endpoints : The incidence of grade 3 and 4 adverse events (AEs) following  12 weeks of 
treatment with SOF/ VEL /VOX  in HCV infected subjects who have  previously 
failed FDA approved DAA -based  therapy .  
 
The proportion of subjects who achieve sustained virologic response 12 weeks after 
completion of treatment, SVR 12. 
  
Secondary  
Endpoints : 1. Correlation and comparison of the slope of HCV viral load decline (early viral 
kinetics) with end of treatment response (ETR) and sustained virologic response 4, 
12, and [ADDRESS_1044341] treatment in patients with early and advanced stage liver 
disease, in  patients with HCV GT 1 subtypes  a and b , and in patients who 
previously failed d ifferent combination DAA therapi[INVESTIGATOR_014] . 
 
 2. Comparison of HC V viral kinetics (VK) and pharmacodynamic (PD) parameters 
in subjects who achieve SVR and those who do not.  
 
 3. Perce ntage and comparison of subjects who achieve ETR, SVR 4 and SVR 24 in 
patients with early and advanced stage liver disease, in patients with HCV GT-1 
subtypes  a and b , and in patients failing different combination DAA therapi[INVESTIGATOR_014] . 
 
 4. Comparison of pharmacokinetics (PK) of SOF/ VEL /VOX  in subjects who 
achieve SVR and those who do not.  
 
 5. Comparison of differential interferon sensitive gene (ISR) response to therapy in 
patients who do and do not attain SVR, as well as in subgroups of pa tients with 
early as compared to advanced liver disease, in patients with HCV GT-[ADDRESS_1044342] genetic/proteomic factors associated with differential response 
to SOF/VEL /VOX  overall and in subgroups of patients with early an d advanced 
stage liver disease , in patients with HCV GT-1 subtypes  a and b , and in patients 
failing different combination DAA therapi[INVESTIGATOR_014] . 
 
 7.  Evaluation of HCV quasispecies fitness at baseline, du ring therapy, and at the 
time of viral relapse to determine the emergence of resistant HCV and 
immunologic (adaptive and innate) correlates of SVR.  
  
 8. Changes in HCV specific CD8 responses in patients  with cirrhosis and not with 
cirrhosis . 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 13 of 55 
   
 9. Changes  in HCV  specific immune responses in patients  treated with single 
(NS5B) DAA versus dual (NS5B + NS5A) versus triple combination DAA (NS5B 
+ NS5A + NS30 ) using samples from SPARE , SYNERGY,  and this study  
 
 
Study  
Duration :       Subjects will be evaluated by 10 clinic visits over  approximately  38 weeks.    
 
STUDY SCHEMA   
    

RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 14 of 55 
 1 INTRODUCTION AND RAT IONALE  
1.1 CHRONIC HEPATITIS C INFECTION : BACKGROUND   
Chronic hepatitis C virus (HCV) infection is a major public health problem with an estimated 
180 million people infected worldwide1. In the [LOCATION_002], an estimated 2.7 million people are 
infected2. HCV is the principal cause of death from liver disease and leading indication for liver 
transplantation in the Western world3,4. According to the CD C, in 2013, over 19,000 deaths were 
attributed to HCV infection and its complications , although this is likely an underestimate, by [CONTACT_762383]5. HCV now surpasses human immunodeficiency virus as a 
cause of death within the Unit ed States6. Of those patients with chronic HCV infection, as many 
as 20% are estimated to go on to develop complications including cirrhosis, end -stage liver 
disease, and hepatocellular carc inoma (HCC)7. Until recently, standard of care treatment with 
pegylated interferon (pegIFN) and ribavirin (RBV) was associated with low response rates8,9, 
from 27 -39%, depending on the patient population, but was associated with complicated drug 
interactions and high rates of toxicity, including psychiatric illness, constitution al side eff ects, 
and cytopenias.  
Recent advances in therapy have dramatically improved the prognosis of those with chronic 
HCV infection.  The development of directly -acting antivirals  (DAAs)  represents  a major 
advance in HCV  treatment. Modern combination DAA -based  regimens are shorter in duration, 
better tolerated, and result in higher sustained virologic response (SVR) rates than prior 
therapi[INVESTIGATOR_014]. The safety and efficacy of combination DAA -based  regimen s has been demonstrated 
in patients with a broad range of disease  stages from patients naïve to HCV therapy with minimal 
fibrosis to patients with advanced fibrosis and cirrhosis who have failed previous interferon -
based therapi[INVESTIGATOR_014]10-15. Even patients failing early s ingle DAA therapi[INVESTIGATOR_762357] a fixed -dose combination (FDC) of ledipasvir (LDV) and 
sofosbuvir (SOF)16, with excellent safety and tolerability profiles 17,18.   
 
1.[ADDRESS_1044343] 
demonstrated high response rates (>90%) after previous failure of a short course regimen19, 
despi [INVESTIGATOR_762358] (RAVs) , others have reported low 
treatment response rates , in some cases less than 50% , related to treatment emergent  NS5A 
RAVs20. In these small studies, it  is unclear whether viral , treatment  or host factors drive the low 
response rates.  This study seeks to address this question and determine whether a universal 
“salvage” regimen would be safe, tolerable, and effective in patients failing a diverse array of 
combination DAA -based therapi[INVESTIGATOR_014].   
Sofosbuvir , a nucleotide analogue chain terminating inhibitor of the NS5B HCV viral 
polymerase,  was approved by [CONTACT_546080] 2013 , and of note, treatment emergent 
resistance t o NS5B inhibitors has not be en observed in patients failing SOF -based regimens21. 
The investigational agents Velpatasvir (VEL , formerly GS-5816 ) which inhibits the NS5A 
protein, and Voxilapravir , the NS3/[ADDRESS_1044344] shown promise in early clinical 
studies22-24, including efficacy of approximately 90% in patients who had previously failed 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044345] previously failed combination 
DAA therapy , including LDV /SOF, paritaprevir/ritonavir/ombitasvir/dasabuvir ( PrOD ), and 
elbasvir/grazoprevir (EBR/GZR) -based combination DAA regimens , we hypothesize that 
retreatment  with at least two novel drugs will be safe and effective, overcom ing baseline or 
treatment emergent viral resistance and inhibit ing viral replication.  
 
1.3 RATIONALE  FOR  SELECTION  OF ALL OWED  CONCOMITANT  ARV  
REGIMENS  
HIV ARV regiments allowed in this study include  emtricitabine (FTC)/tenofovir alafenamide 
(TAF ), FTC/tenofovir disoproxil fumarate (TDF) , or abacavir  (ABC)/lamivudine ( 3TC) plus:  
 Riton avir (r) and darunavir (DRV), or  
 Raltegravir (RAL), or  
 Elvitegravir (E VG)/Cobicistat ( c), or  
 Rilpi[INVESTIGATOR_12979] (R PV) 
Fixed dose combinations of approved regimens (ie, F TC/TAF [Descovy], E VG/c/FTC/TAF 
[Genvoya], R PV/FTC/TAF [Odefsey], F TC/TDF [Truvada] E VG/c/FTC/TDF [Stribild], 
RPV/FTC/TDF [Co mplera]) will be allowed as part or all of an approved ARV regimen. 
Alternative ARV  regimens will be considered on an individual basis, based on available drug -
drug interaction (DDI) data at the discretion of the principal investigator . 
 
Protocol -approved ARV regimens were selected based on the results from the DDI studies that 
demonstrated  co-administration of these ARVs with SOF/VEL/VOX would not require dose 
adjustment to any of these agents (Study GS -US-367-1657 [Section Error! Reference source 
not found. ]; Study GS -US-380-1999 [Section Error! Reference source not found. ]. The 
protocol -approved ARV regimens must be administered as indicated in the prescribing 
information of the package insert for the treatment of HIV infection.  
 
1.4 SOFOSBUVIR  
Sofosbuvir  (SOF)  is an FDA -approved nucleotide analog that is a potent and selective inhi bitor 
of the NS5B  HCV polymerase  and was approved for the treatment of HCV infection by [CONTACT_762384] [ADDRESS_1044346] insert for additional information . 
 
 
1.5 SOF/ VEL   
Epclusa (SOF/VEL) in an FDA -approved fixed dose combination (FDC)  of SOF and the NS5A 
inhibitor Velpatasvir (VEL). This combination was approved by [CONTACT_407022] [ADDRESS_1044347] insert for 
additional information.  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 16 of 55 
 1.6 SOF/VEL /VOX    
1.6.1  Voxilaprevir  
Voxilaprevir ([COMPANY_009] product no. GS-9857 ) is a novel macrocyclic HCV NS3 protease inhibitor 
with potent in vitro antiviral  activity against genotypes [ADDRESS_1044348] coverage of NS 3 
protease polymorphs, and an  improved resistance profile compared with PIs approved by [CONTACT_5212]  (FDA) or currently in clinical development. Please refer to the IB 
for SOF/VEL/ VOX  for additional information on  Voxilaprevir  including : 
 In Vitro  Anti-Hepatitis C Virus Activity  
 Nonclinical PK and In Vitro Metabolism  
 Nonclinical Pharmacology and Toxicology  
 Clinical Experience  
 
1.6.2 Summary of Clinical Experience with SOF/VEL /VOX  
Data from three Phase 2 studies,  GS-US-337-1468 (LEPTON), GS -US-367-1168, and 
GS-US-367-1169 , support the efficacy of 12 week therapy with SOF/VEL/ VOX  in subjects with 
DAA experience. In the LEPTON study, 67% (20/30) subjects who had previously failed 
2 DAAs and then received 6 weeks of SOF/VEL+ VOX achieve d SVR12. I n Study GS -US-367-
1168, 100% (63/63) genotype 1 subjects that had previously failed DAAs  and received 12 weeks 
of SOF/VEL+ VOX  achieved SVR 12. In study GS -US-367-1169, 98.5% (64/6 5) subjects 
infected with genotypes 2 -6 HCV who w ere treatment experienced , including 38 subjects who 
had failed a DAA , and received 12  weeks of SOF/VEL+ VOX  achieved SVR 12. Treatment was 
safe and generally well tolerated. No safety signal associated with the administration of these 
agents was identified.  
1.6.3 FDA -approval  
The fixed dose combination with SOF/VEL/VOX was approved in the U.S. by [CONTACT_8956] 17 
July 2017  and is indi cated for the treatment of adult patients with chronic HCV infection without 
cirrhosis or with compensated ci rrhosis (Child -Pugh A) who have :  
• genotype 1, 2, 3, 4, 5, or [ADDRESS_1044349] previously been treated with an HCV regimen 
containing an NS5A inhibitor.  
• genotype 1a or [ADDRESS_1044350] previously been treated with an HCV regimen containing 
sofosbuvir without an NS5A inhibitor.  
 
1.6.4  Phase 3 Studies with Vosevi  
The efficacy of VOSEVI was evaluated in two Phase 3 trials (GS-US-367-1171 [ POLARIS -1], 
GS-US-367-1170 [POLARIS -4] in DAA -experienced subjects with genotype 1, 2, 3, 4, 5, or 6 
HCV infection without cirrhosis  or with compensated cirrhosis. In these studies, 445 subjects 
received SOF/VEL/VOX (400/100/100 mg). The results from these  studies are described within 
the Package Insert , but across all POLARIS studies, the efficacy of SOF/VEL/VOX ranged from 
95-97%. The most common (at least 10%) adverse reactions were headache, fatigue, diarrhea, 
and nausea .  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 17 of 55 
 1.7 PHARMACOKINETICS OF SOF/ VEL /VOX 
Please refer to the  Vosevi ( SOF/VEL/ VOX ) package insert  for information on the 
pharmacokinetics of these agents.  
 
1.8 SAFETY OF SOF/ VEL /VOX  
To date, over [ADDRESS_1044351] received SOF/VEL+ VOX clinical  studies and there have been 
no clinical safety issues identified. There is no expectation of significant overlappi[INVESTIGATOR_762359], 
unexpected toxicities upon coformulation of SOF/VEL with VOX  as an FDC; data from study 
GS-US-367-1176 comparing SOF/VEL+ VOX  with SOF/VEL/ VOX - were consistent with this. 
However, a potential risk of the study includes the identification of previously undetected 
adverse effects.  
There is a potential risk for subjects to develop multiclass resistance if treatment in this study is 
unsu ccessful. However, VOX  has the highest reported barrier to resistance among NS3/4A PIs 
and so the anticipated clinical risk of developi[INVESTIGATOR_21395] -resistant mutants with VOX  is anticipated 
to be lower than that associated with first and second generation NS3/4 A PIs 26. Accordingly, 
there was a lack of any viral breakthrough during therapy with VOX  in the 3 -day monotherapy 
study. Mutants generated in vitro to be resistant to VOX remain sensitive to SOF and VEL , 
supporting the clinical use of VOX  in combination with other classes of HCV i nhibitors. Lastly, 
this risk is balanced by [CONTACT_762385]/VEL+ VOX  in Phase 2 
studies and a very low rate of emergent resistance among subjects who relapsed.  
 
Please see the Investigators Brochure for SOF/VEL/ VOX  for further information about 
SOF/VEL/ VOX . 
 
1.9 RATIONALE FOR DOSE SELECTION OF SOF/VEL/ VOX  
Sofosbuvir 400 mg, once daily is the approved marketed dose of SOF for the treatment of HCV 
infection.  
Velpatasvir 100 mg has been administered in combination with SOF for 12 week s to more than 
1500 subjects infected with HCV genotypes 1 -6 in Phase 2 and 3 studies. The favorable safety 
and efficacy profile of this combination support selection of SOF 400 mg and VEL 100 mg for 
co-formulation into an FDC with VOX .  
Voxilaprevir 100 m g dose was selected for co -formulation with SOF 400 mg and VEL  100 mg 
based on the anti -HCV activity of VOX  established in the phase 1 study GS -US-338-1121 (50 – 
300 mg VOX  dose evaluated).  
Results from the relative bioavailability study GS -US-367-1176 show that the SOF/VEL/ VOX  
FDC formulation achieves similar exposures of the relevant analytes to those observed with 
SOF/VEL+ VOX . Additionally, the favorable safety and efficacy profile of SOF/VEL+ VOX  
from Phase 2 studies support further evaluation of the combination of SOF/VEL/ VOX  
400/100/100 mg.  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 18 of 55 
 1.10 OVERALL RISK/BENEFIT ASSESSMENT  
The potential benefits of SOF/ VEL /VOX  for the treatment of chronic HCV for patients included 
in the current study population are:  
 Addressing the unmet medical need of the growing p opulation of patients who have failed 
prior therapi[INVESTIGATOR_014], particularly t hose including DAAs such as SOF;  
 Provision of a once -daily, single tablet, pangenotypic therapy for patients who have failed 
prior therapi[INVESTIGATOR_762360].  
Based o n the well -characterized nonclinical toxicology profile of SOF, VEL, and VOX , and the 
clinical experience with SOF, VEL, and VOX , there is no expectation of significant overlappi[INVESTIGATOR_762361], unexpected toxicities upon adm inistration of SOF/VEL/ VOX . 
There is a potential risk for subjects to develop previously undetected adverse events or 
multiclass resistance . However, the development of resistance is anticipated to be low due to the 
high efficacy rate of the SOF/VEL + VOX  combination therapy , as seen in Phase  [ADDRESS_1044352] -generation PIs in combination with Peg -IFN+RBV. If high rates of SVR 
can be obtained wit h a 12 -week pangenotypic regimen, the anticipated value of achieving an 
SVR for patients with no current therapeutic options, with a safe and tolerable regimen, offers a 
favorable risk -benefit determination.  
 
2 STUDY DESIGN AND METHODS  
This is a Phase IIb, open -label , study  to evaluate the safety, tolerability, and efficacy of 
SOF/ VEL /VOX  in subjects with chronic HCV infection who have failed to eradicate HCV in 
response to combination DAA -based therapy , including subjects coinfected with HIV .  We will 
also evaluate the viral mutants, HCV quasispecies, as well as immunologic, virologic, and host 
genetic/proteomic predictors of response to SOF/ VEL /VOX  in study subjects.  
We hypothesize that the combination SOF/ VEL /VOX  will result in high SVR rates in patients 
with chronic HCV infection who are treatment -experienced after previous combination DAA -
based therapy with an FDA -approved regimen , including  LDV/SOF and  Viekira Pak 3D regimen 
consisting of  paritaprevir (co -dosed with ritonavir [paritaprevir/r]), ombitasv ir, dasabuvir  
(PrOD) , dosed with or without ribavirin (RBV).  
All participants will receive 12 weeks of SOF/ VEL /VOX . Patients  will be followed for 
approximately 44 weeks from the screening period through the end of follow up visits:  
 8-week screening period  
 12-week treatment period  
 12-week post-treatment follow -up visit  (SVR 12) 
 24-weeks post -treatment visit to assess late viral relapse.  
Subjects that experience virologic failure or relapse and identified to have mutations leading to 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 19 of 55 
 SOF, VEL , and/or VOX  resistance , following sequencing and phenotypic , analysis will be 
requested to return at 12 -week intervals for this or a natural history protocol for up to 44 weeks 
to determine the time required for the resistant virus to return to background levels.  
2.1 PRIMARY  OBJECTIVE  
 To assess the safety, tolerability, and efficacy of 12 weeks of SOF/ VEL /VOX  in subjects 
with chronic HCV infection who have previously failed FDA approved DAA -based 
therapy, with compensated cirrhosis and without cirrhosis , with and without HI V 
coinfection .   
2.2 SECONDARY OBJECTIVES  
 To evaluate the immunologic, virologic, and host genetic/proteomic predictors of 
response to therapy with SOF/ VEL /VOX  in HCV infected subjects who have failed 
previous combination DAA -based therapy  
 To compare HCV quasis pecies and resistance associated variants (RAVs) from baseline 
and throughout treatment, especially in the case of relapse or breakthrough, and assess 
the influence of past DAA experience on evolution of RAVs and on virologic response to 
treatment.  
 To dete rmine the kinetics of plasma HCV RNA during treatment and after treatment 
discontinuation .  
 To evaluate the effect of SOF/ VEL /VOX  on peripheral markers of T cell activation.  
 To evaluate the proportion of subjects whose alanine aminotransferase (ALT) levels  
normalize between baseline and SVR 4,12,24. 
 To delineate the precise effects of specific HCV lifecycle inhibitors on host immune recovery in 
patients receiving single (SPARE), or combination DA therapy ( RESOLVE ). 
  
2.3 EXPLORATORY OBJECTIVES  
 Characterize i mmunologic, virologic, and host genetic/proteomic predictors of response  
 Viral kinetic investigations, including early viral kinetics, resistance associated variants, 
HCV quasispecies  
 To determine the impact of liver cirrhosis in SVR when treated with pote nt combination 
DAA therapy  
 To delineate the precise effects of specific HCV lifecycle inhibitors on host immune 
recovery in patients receiving combination DAA therapy  
 To compare the immunophenotypic responses of patients receiving SOF/ VEL /VOX  who 
have previously failed double and triple DAA therapy.  
2.3.[ADDRESS_1044353] immunity that is associated with SVR. Studies on 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 20 of 55 
 B and  T cell responses in HCV or HCV/HIV dual infection and the relationships to 
treatment outcomes require large numbers of patients and extensive clinical trials of DAA 
therapy. Our research  team is making a major impact on the clinical unde rstanding of DAA . 
We h a v e  collected and maintain a large specimen repository that is sufficient for our initial 
characterization of B and T cells and how they are related to protective immunity. 
Chronic HCV infection is characterized by [CONTACT_762386]. DAA 
therapy is successful in resolving HCV infection and provides cure in up to 99% cases, except 
for late stage disease. Whether cure is associated with reconstituted immune regulation and 
what role the adaptive immune system plays in viral clearance is not known. Faster 
resolution of secondary infection after spontaneou s clearance of HCV in humans and in 
chimpanzees points to a role for immunological memory in HCV control. Defining the immune 
correlates of DAA mediated sustained virologic response will help unde rstand the immune 
defects that may be associated with treatment failure. 
 
Hypo thesis  
Hypothesis #1 : Augmentation of HCV specific cellular immune responses with DAA therapy is 
associated with SVR.  
Hypothesis #2 : Healthy (non cirrhotic) liver is critical in mounting HCV specific cellular 
immunity in DAA treated patients  
Hypothesis #3 : Specific inhibitio n of stages of HCV lifecycle leads to precise immune recovery 
in chronic HCV infected patients treated with combination DAA therapy . 
 
Study Design and Analysis  
 
To achieve these objectives, we will analyze peripheral and intrahepatic cellular immunity in 
patients who are cirrhotic and those who are not , as described in detail below. The 
responses/changes observed over time with DAA therapy will be compared between the two 
groups to evaluate first objective.  
 
  
 
 
To address the second objective, we will u tilize samples collected from previous studies that 
used either single DAA (SPARE), dual or multiple DAA therapy (present study) to determine the 

RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044354] of specific HCV lifecycle inhibitors (NS5B alone, NS5B with NS5A and 
NS5B with NS5A and NS 3 inhibitors). The assays that will characterize peripheral and 
intrahepatic cellular immunity are described in detail below. The changes from baseline to the 
end of therapy (or full viral suppression) will be compared in all patients receiving various 
regimens to determine the differential effect of added suppression of NS5A and or NS3.  
 
 
 
 
2.[ADDRESS_1044355] (IRB) -
approved advertising  to HCV providers  and screened to confirm eligibility requirements for 
participation.   
The following eligibility criteria will b e used:  
2.4.[ADDRESS_1044356] meet all of the following criteria:  
1. At least 18 years of age or older at screening . 
2. Available for clinical follow -up through Week 44 after enrollment.  

RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 22 of 55 
 3. Recurrent HCV GT -1 infection as documented by ≥ 1 measurement of serum HCV 
RNA ≥ 1,000 IUM/mL during screening and  documented history of receiving prior 
HCV treatment.   
4. Exposure to  combination  DAA  therapy , including , but not limited to, the  following 
regimens:  
a. LDV/SOF ± RBV   
b. Viekira Pak ± RBV  
c. EBR/GZR ± RBV  
 
5. Ability to communicate effectively with the study investigator and other key personnel.  
 
6. Opi[INVESTIGATOR_2480] -dependent individuals must be participating in a supervised treatment program  
or considered stable at the discretion of the investigator . 
 
7. Subjects must have a primary care doctor for their medical management.  
8. Able and willing to complete the informed consent process.  
9. Willing to donate blood for sample storage to be used for future research.  
10. Female study participants with childbearing potential (as defined below) and all 
male  study participants must be willing to practice either:  
 
 Complete a bstinence from sexual intercourse with a member of the opposite sex  
OR 
 At least one form  of effective contraception from the list below, in additio n to correct 
use of either a male or female condom with spermicide, throughout dosing and for a 
defined period following the last dose (30 days for women, 14 days for men)  of 
study medication .: 
i. Intrauterine device with a failure rate of <1% per year  
ii. Tubal sterilization  
iii. Bilateral tubal occlusion  
iv. Vasectomy in a male partner   
v. Femal e barrier method (diaphragm or cervical cap) with spermicide  
vi. Hormonal methods  
1. Oral contraceptives  
2. Injectable progesterone  
3. Implants of levonorgestrel or etonorgestrel  
4. Transdermal contraceptive patch  
5. Contraceptive vaginal ring  
11. Hepatitis B coinfected participants , must have evidence of chronic infection and 
controlled on treatment.   
12. HIV coinfected participants only must have HIV status of one of the following:  
a. HIV untreated for ≥8 w eeks prior to Screening  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 23 of 55 
 i. CD4 T -cell count >500 cells/mm3 at Screening  
ii. No intention of initiating ARV therapy for the duration of trial  
   OR 
b. HIV suppressed  on a stable, protocol -approved, ARV regimen for ≥ [ADDRESS_1044357] 3 months of any prior HIV ARV therapy and 
maintained HIV RNA < 50 copi[INVESTIGATOR_014]/mL (or < LLOQ if the local 
laboratory assay’s LLOQ is ≥50 copi[INVESTIGATOR_014]/mL) prior to Screening. Subjects 
with an isolated or unconfirmed HIV RNA > 50 copi[INVESTIGATOR_014]/mL (or > LLOQ 
if the local laboratory assay’s LLOQ is ≥50 copi[INVESTIGATOR_014]/mL) are not 
excluded.  
ii. CD4 count >100 cells/mm 3 at Screening  
iii. HIV antiretroviral (ARV) agents allowed in this study include  
 FTC/TAF [Descovy ®], FTC/TDF [Truvada ®], or ABC/3TC 
[Epzicom ®] 
 
plus 
 
 Ritonavir (r ) and darunavir (DRV), OR  
 Raltegravir (RAL), OR  
 Elvitegravir (EVG) ± Cobicistat (c), or  
 Rilpi[INVESTIGATOR_12979] (R PV) 
 
Or 
 
Fixed dose combinations as below  
 FTC/RPV/TAF [Odefsey ®] 
 FTC/RPV/TDF [Complera ®] 
 EVG/c/TAF/FTC  [Genvoya ®] 
 EVG/c/TDF/FTC  [Stribild ®] 
 
Alternative ARV regimens will be considered on an individual basis, 
based on available DDI data at the discretion of the principal 
investigator  
[CONTACT_245282]. The subject is expected  to continue the current ARV regimen for the 
duration of the trial  
Cirrhosis Criteria:  
13. Liver fibrosis staging as determined by [CONTACT_762387]/IDSA guideline -approved 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 24 of 55 
 measurement, within three years of Screening , including any one of the following:  
a. Imaging  
b. Liver biopsy  
c. Transient elast ography   
d. Noninvasive markers  
Liver imaging within 6 months of Day  0 to exclude hepatocellular carcinoma (HCC) is required 
in patients with cirrhosis.  
2.4.[ADDRESS_1044358] will be excluded if one or more o f the following conditions apply:  
1. Combination DAA therapy was completed or discontinued less than 8 weeks  prior to 
enrollment.  
2. Current or prior history of any of the following:   
a. Clinically significant illness (other than HCV) or any other major medical 
disorder that may , in the opi[INVESTIGATOR_871],  interfere with the subject 
treatment, assessment of  compliance with the protocol; subjects currently under 
evaluation for a clinically -significant illness (other than HCV) are also excluded  
b. Gastrointestinal disorder with post -operative condition that could interfere with 
the absorption of the study drug s  
c. Poor venous access interfering with required study blood collection  
d. Hepatic impairment  or decompensation  (e.g., Child -Pugh class B [moderate] or 
Child -Pugh class C [severe])  
e. Solid organ transplantation  
f. Significant pulmonary disease, significant cardiac disease , or porphyria.  
g. Unstable psychiatric disease , including hospi[INVESTIGATOR_059], suicide attempt, and/or a 
period of disability as a result of their psychiatric illness within 2 years prior to 
Screening  (subjects with psychiatric illness that is well -controlled on a stable 
treatment regimen or currently not requiring medication may be included)  
h. Any malignancy or its treatment that in the opi[INVESTIGATOR_762362] y; subjects under evaluation for malignancy are 
not eligible  
i. Chronic liver disease of a non -HCV etiology (e.g., hemochromatosis, Wilson’s 
disease, alfa -1 antitrypsin deficiency, cholangitis)  
3. Abnormal hematological and biochemical parameters at screening, unless the test has 
been repeated and at least one subsequent result is within the acceptable range prior to 
study drug administration, including:  
a. Neutrophil count <750 cells/mm3  
b. Hemoglobin level < 10 g/dL  
c. Platelet count ≤50,000 cells/mm3 
d. Estimated glomerular filtration rate, calculated by [CONTACT_762388][INVESTIGATOR_762363]: < 30 mL/min/1.[ADDRESS_1044359] level ≥10 times upper limit of normal (ULN)  
f. Serum lipase level ≥1.[ADDRESS_1044360] at screening or during the screening period  
in a patient with symptoms of pancreatitis  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 25 of 55 
 g. Total bilirubin level ≥2.[ADDRESS_1044361], except in subjects with Gilbert’s 
syndrome  or other clinical explanation at the discretion of the PI.  
h. Albumin level < 3 g/dL  
 
4. Poorly controlled diabetes as indicated by a scr eening glycosylated hemoglobin 
(HbA1c) >10  
5. Known hypersensitivity to any of the study medications  
6. Screening ECG  with clinically significant findings  
7. Need for the use of the following medications from 21 days prior to the start of study 
drugs through the e nd of treatment:  
a. Hematologic stimulating agents, erythropoiesis stimulating agents (ESAs), 
granulocyte colony stimulating factor (GCSF), thrombopoeitin (TPO) mimetics  
b. Chronic systemic antineoplastic or immunomodulatory treatment including 
supraphysiologic  doses of immunosuppressants such as corticosteroids (e.g., 
prednisone equivalent >10 mg/day for >2 weeks), azathioprine or monoclonal 
antibodies (e.g., infliximab)  
c. Investigational agents or devices for any indication  
d. Use of certain medications and herbal/ natural supplements per PI [INVESTIGATOR_9106], 
expected to result in increases or decreases in exposure to study or non -study 
medications as listed in  section  3.5 (Table 3 -1). 
 
8. Any medical, psychiatric, social condition, occupational reason or other responsibility 
that, in the judgment of the investigator, is a contraindication to protocol participation 
or impairs a volunteer’s ability to give informed consent.  
Female -specific criteria : 
9. Woman who is breast -feeding or planning to become pregnant during the first 24 weeks 
after study  drug administration . 
2.5 PHARMACOKINETIC AND VIRAL KINETIC SUBSTUDY  
Participants, N=20 (10 participants with cirrhosis and 10 without cirrhosis) that meet the above 
criteria and who are willing to participate will be eligible for a voluntary 24 hour and 72 hour  
pharmacokinetic (PK) and viral kinetic (VK) substudy.  
 
2.6 RECRUI TMENT PLAN 
The study will be advertised and po sted using flyers.  All advertisements will be IRB approved 
before use.  
 
2.7 HUMAN SUBJECTS PROTECTIONS  
Subjects will be fully counseled prior to entry into the study as to the potential risks of the study  
and cons enting using good clinical practice . Subjects who, in the opi[INVESTIGATOR_57455], do 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044362] not been evaluated; therefore, pregnant or nursing 
women will be excluded from this study. Any woman of child -bearing potential must have a 
negative pregnancy test on Day [ADDRESS_1044363] dose of SOF/VEL /VOX  and use 
effective contraception throughout the study.  
 
2.7.[ADDRESS_1044364] use of a condom 
with spermicide, from 2 weeks prior to Day 0 until after completing study drug ([ADDRESS_1044365] or partner, during and after treatment is important as the risks are as yet 
unknown.  
 
Definitions:  
a. Definition of Childbearing Potential : For the purposes of this study, a female born subject is 
considered of childbearing potential from menarche until becoming post -menopausal, unless 
permanently sterile or with medically documented ovarian failure.   
 
Women are considered to be in a post -menopausal state when they are > 54 years of age with 
cessation of previously occurring menses for > [ADDRESS_1044366] of any age.  
 
b. Definition of Male Fertility: For the purposes of this study, a male born subject is considered 
of fertile after the initiation of puberty unless permanently sterile by [CONTACT_762389].  
 
 
2.8 CLINICAL PROCEDURES AND SCHEDULE  OF EVALUATIONS  
This section describes the clinical procedures for evaluating study participants and follow -up 
after administration of study drug.    
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 27 of 55 
  
Study visits, including screening, will occur at the UMB I nstitute of Human Virology  clinic or  
one of the  clinics mentioned in the study roster based upon scheduling availability to 
accommodate each treatment group. Participants in the pharmacokinetic or viral kinetic substudy 
will be seen at the University of Maryland Medical Center . 
 
UMB Study Te am Roles at Washington, DC community clinics:  Members of the study team 
have been actively involved in patient care at the community clinics (Unity’s Park side and 
Walker -Jones). Unity  will sign a UMB Reliance Agreement prior to initiating any study 
activi ties. The site AI and collaborating investigator  may see subjects at non -study visits and will 
communicate findings to UMB  study team. The UMB research coordinators will also oversee 
research operations in the clinics and at the UMB IHV clinic.  The UMB study staff will see 
participants for all scheduled and unscheduled visits and study withdrawal.  
 
If subjects are seen in the Community: All phlebotomy will be done by a phlebotomist 
working in the clinic or clinic staff. A specimen bag and specimen tubes will be prepared by 
[CONTACT_762390]’s first three initials of last and first name [CONTACT_628512].  All laboratory studies will be performed by [CONTACT_762391] a weekly basis. Copi[INVESTIGATOR_17455] w ill be sent to the primary care provider and 
scanned into the electronic medical record at the participating clinic.  
Clinic staff will not participate in study -related visits unsupervised by [CONTACT_762392]. 
Participants will be given a calendar of schedul ed study visits and will be informed that any 
clinic visits outside of scheduled study visits may be either unscheduled visits or non -study 
visits. All visits related to the treatment of HCV will be considered study related. Any other 
medical problems will  be addressed by [CONTACT_2299]’s primary provider. Participants will 
receive this information when given the visit calendar.  
The primary responsibility of the site AI and the community clinics is to provide timely and 
effective communication regarding any potential adverse events if a subject/patient is seen for 
care outside of the normal study visit.   
 
2.8.1 Screening  
Each patient w ill provide informed consent of his/her free will prior to commencement of any 
study procedures according to ICH and Code of Federal Regulations (CFR).  Each patient will be 
provided a copy of the signed informed consent form.  
 
After a patient has provided  informed consent, the Investigator and other study personnel will 
determine if the patient is eligible for participation in the study.  Screening may begin up to [ADDRESS_1044367] dose of study drug (Day 0)  and is indicated for disease staging  as 
specified in the inclusion criteria. An optional research liver biopsy will be offered to subjects 
during screening (and at end of treatment) with the aim of having paired research samples on up 
to 20 subjects on the study.   
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 28 of 55 
 Screening will include a review of the inclusion/exclusion criteria and completion of all 
screening procedures as outlined in the Schedule of Tests , Section  5.1. Screening tests within  the 
last [ADDRESS_1044368] been done as part of routine medical care  or at an 
outside facility (with the exception of chemistries, hCG, HIV, CBC with differential, coagulation 
studies) can be used if within the acceptable time fra me. Known HIV infected participants will 
not have an HIV test, but will hav e HIV RNA and  CD4 T -Cell count  testing.  
  
The standard consent includes permission for HIV testing  (in those not previously known to be 
infected) , optional liver biopsy , and storage of blood and tissue samples. HLA testing may be 
tested  for this study if not on file, because this information will be useful  for the evaluation o f 
HCV -specific immune responses.   
 
Screening procedures do not need to be repeated within the [ADDRESS_1044369] (if 
appropriate per visit day, see Schedule of Tests , Section 5.1), clinical laboratories drawn, and a 
review of the study restrictions.  Subjects will be asked abou t their state of health and use of any 
concomitant medication since the previous study visit.  They will also be questioned about AEs , 
their adherence with study restrictions , and their adherence to study drug administration . A 
complete list of study procedures and lab tests to be performed is in the Schedule of Tests , 
Section 5.1.  
 
In addition, subjects may be seen at unscheduled visits for a grade 3 or 4 AE or any unexpected 
AE (adverse event) or potential toxicity.  
 
Some of the visits have flexibi lity regarding when they need to occur. The window period for 
visit schedules is as follows:  
 Days 0, 3 (PK/VK participants only),  no window  
 Optional Week 1 (+/ - 3 days)  
 Weeks 2, 4 (+/- 3 days)  
 Weeks 8 and 12  (+/- 7 days)  
o Optional End of therapy  Liver Biopsy (+/ -14 days)  
 Post Therapy Week s 4, 12, 24 (+/- 10 days)  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 29 of 55 
 2.11 STARTING SOF/VEL /VOX  (DAY 0) 
The participant will be started on SOF/VEL /VOX  on Day 0. Blood will be drawn for HCV viral 
loads, immunologic studies, and for storage prior to dosing. A pr egnancy test will be done for 
females with childbearing potential and the pregnancy test must be negative prior to dosing with 
study drugs.   The subject will undergo a history and physical exam on Day 0, prior to starting 
study medications.  
 
2.12 OPTIONAL PK/V K SUBSTUDY  
Participants who are eligible and interested in participating in the optional PK/VK substudy will 
undergo timed blood draws at baseline, 1, 2, 4, 8, [ADDRESS_1044370] been met. Subjects who fail to achieve > 2 log 10 HCV RNA drop at this 
time (unless > 2 log drop would be below LLOQ) will be discontinued from therapy  unless a 
review by [CONTACT_978]/LAI/Medical Monitor (MM) determines otherwise , and the last bottle of study 
medication will be dispensed.  
 
2.[ADDRESS_1044371] been met.  
 
2.17 WEEK 12 / END OF TREATMENT VISIT   
Week [ADDRESS_1044372] dose of SOF/VEL /VOX  FDC  to be administered. In addition, if a 
patient’s participation terminates prior to Week 12, the Week 12 assessments may be performed 
at any end -of-treatment visit.  
 
2.18 FOLLOW -UP VISITS AFTER STUDY DRUG DISCONTINUATION  
After discontinuation of the study drug, subjects will be followed at Weeks 4, 12,  and 24 after 
completion of therapy . All subjects will be assessed for sustained virologic response (SVR 12) at 
the post -treatment week [ADDRESS_1044373] will be done 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044374] received SOF/ VEL /VOX  FDC  will be evaluated for safety. 
Safety will be assessed by [CONTACT_5292], vital signs, hematology, and chemistr ies. The 
severity of signs, symptoms, and AEs will be determined by [CONTACT_10540] [ADDRESS_1044375] returned to the normal range and/or an adequate 
explanation of the abnormality is found.  If a clear explanation is established it should be 
recorded.  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044376] treatment 
described in Dose Mod ification  and Treatment Failure  Sections, t he Investigator or designee also 
has the right to withdraw subjects from the study for any of the following:  
1. Development of life -threatening infection (requiring with drawal of study drugs for more 
than 6 weeks) or malignancy.  
2. Participant’s desire to leave study.  
3. Pregnancy or breastfeeding.  
4. Participant’s non -compliance. If a subject misses 5 or more total study visits or > [ADDRESS_1044377] will be rem oved from the protocol at the discretion of the 
Investigator or designee.   
5. Termination of study.  
6. Development of liver decompensation with elevated Child -Turcotte -Pugh score of 8 or 
more.  
7. If SOF/ VEL /VOX  FDC is permanently discontinued by [CONTACT_762393].  
8. Development of a medica l condition, such as hepatocellular carcinoma, that in the 
opi[INVESTIGATOR_689], it is in the subject’s best interest to discontinue study dr ug 
even if criteria requiring drug discontinuation have not been met.  
9. Request of the primary care provider or Investigator if s/he thinks the study is no longer 
in the best interest of the subject.  
10. Clinical reasons believed life threatening by [CONTACT_099].  
11. If the subject is judged by [CONTACT_762394]. 
12. Subjects may decide at any point not to have their samples stored. This will be treated as 
a withdrawal of the consent and in this case, the Principal Investigator [INVESTIGATOR_762364] t o both the subject 
and to the IRB. This decision will affect the subject’s participation in this protocol but 
may not affect participatio ns in any other protocols at UMD . 
 
 
[ADDRESS_1044378] or exposure through inhalation when handling study drugs.  
 
3.2 PACKAGING AND LABELING OF STUDY DRUGS  
Each bottle will be individually labeled with the patient ID number, dosing instructions, 
recommended storage conditions, the name [CONTACT_4547], Investigational Use 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 32 of 55 
 Statement (“Caution: New Drug – Limited by [CONTACT_4496] [[LOCATION_003]] Law to Investigational Use”) and 
that the agent should be kept out of reach of children.  
3.2.1 Formulation  
SOF/VEL /VOX  fixed dose combination (FDC) tablets are beige , capsule -shaped, film -coated 
tablets containing 400  mg of sofosbuvir , 100 mg of VEL , and 100 mg of VOX . The tablets are 
debossed with “GSI” on one side  and “3” on the other side . In addition to the active ingredients, 
the tablets  contain the following inactive ingredients: copovidone, microcrystalline cellulose, 
lactose monohydrate, colloidal silicon dioxide, croscarmellose sodium and magnesium s tearate.  
The tablet film -coating material also contains polyvinyl alcohol, titanium dioxide, macrogol/PEG 
3350, talc, iron oxide yellow, iron oxide red, ferrosoferric oxide .   
3.2.2 Packaging and Labeling  
SOF/VEL /VOX  FDC tablets  are packaged in white, high dens ity polyethylene (HDPE) bottles. 
Each bottle contains 28 tablets and a silica gel desiccant canister or sachet and polyester packing 
material. Each bottle is enclosed with a white, continuous thread, child -resistant screw cap with 
an induction -sealed, alum inum -faced liner . 
Sufficie nt quantities of SOF/VEL /VOX  FDC tablets to complete the entire study will be shipped 
from [COMPANY_009] Sciences Materials & Logistics (or its designee).  
3.2.3 Storage and Handling  
SOF/VEL /VOX  FDC  bottles should be stored at controlled room temperature until required for 
administration. Controlled room temperature is defined as 25 C (77F); excursions are permitted 
between 15 C and 30C (59F to 86F). 
All drug products will be stored in a securely  locked area, accessible only to authorized site 
personnel. To ensure the stability of the study drug and to ensure proper product identification, 
the drug product  will not be stored prior to dispensing in a container other than the container in 
which they  are supplied. Consideration should be given to handling, preparation, and disposal 
through measures that minimize drug contact [CONTACT_10850]. Appropriate precautions should be 
followed to avoid direct eye contact [CONTACT_762395]/VEL /VOX  FDC.  
3.3 TREATMENT OF SUBJECTS   
All subjects will receive 12 weeks of treatment with SOF/VEL /VOX . 
SOF/VEL /VOX  FDC  will be administered orally once a day. The 1st dose will be taken on Day 
0.  
3.4 DOSE MODIFICATIONS / TOXICITIES  
Maximal suppression o f HCV replication is most likely accomplished by [CONTACT_762396]. Dose reduction w ould compromise this goal 
and predispose to the emergence of drug -resistant viral variants.  Hence, no dose reductio n will 
be allowed for SOF/VEL /VOX .  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 33 of 55 
 3.4.1 Dose Modification for SOF/VEL /VOX  
Dose modifications will not be permitted. If a subject forgets to take the medication at the correct 
time, it may be taken later in the day; however, no more than a single dose should b e taken on 
any calendar day. The subject should resume the standing dosing schedule on the next day.  Any 
treatment interruption or discontinuation will be recorded including the reason for the 
interruption or discontinuation.  
 
3.4.2 Treatment Failure / Drug Di scontinuation  
See also Criteria for premature withdrawal of subjects  (2.20.2 ). Subjects will be considered 
treatment failures and will discontinue SOF/VEL /VOX  FDC  if they meet any of the following 
criteria while taking study drugs:  
 HCV RNA greater than LLOQ after 2 prior consecutive HCV RNA values 
less than the LLOQ  
 Greater than a 1 log 10 increase in HCV RNA from nadir  
 Less than a 2 log 10 decline in HCV RNA after 4 weeks of treatment  (unless 
>2 log drop would be below LLOQ)  
 HCV RNA ≥ LLOQ after [ADDRESS_1044379] of discontinuation should be  discussed in advance with 
the Medical Monitor ( MM) if possible, particularly if discontinuation is thought to pose a risk to 
the overall clinical wellbeing of the  subject. Those who are discontinued will continue to follow 
the general study schedule of assessments unless unwilling to do so, in which case they may be 
seen at least every [ADDRESS_1044380] stop all stud y medication(s):  
 
 Elevation of ALT >5x OR AST >5x Day 0, confirmed by [CONTACT_199607]  
 Abnormal elevation of ALT >3 x Day 0 and total bilirubin >[ADDRESS_1044381], confirmed 
by [CONTACT_199607]  
 Elevation of ALT >[ADDRESS_1044382] confirmed by [CONTACT_762397]  
 Any Grade 3 or greater rash associated with constitutional symptoms  
 Any Grade 4 event assessed as related to treatment with SOF/VEL /VOX  FDC   
 Pregnancy  
3.4.3 Treatment Failure Criteria After Stoppi[INVESTIGATOR_199599]/ VEL /VOX  
 Have detectable HCV RNA during the post-treatment period (after having achieved 
HCV RNA <LLOQ at end of treatment).   If virus is detected after subject achieves 
SVR12, will confirm with repeat viral testing, and then evaluate for reinfection 
versus relapse with viral subtypi[INVESTIGATOR_762365] g.  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044383]-
baseline visit plasma HIV  RNA levels ≥ 400 copi[INVESTIGATOR_014]/mL (at least two weeks apart) will be 
considered HIV virologic rebound.  
 
Following  an initial HIV RNA result of ≥ 400 copi[INVESTIGATOR_014]/mL, subjects will continue to take 
their current ARV regimen and be asked to return to the clinic after 2 weeks for a 
scheduled or unscheduled blood draw for confirmation of HIV virologic rebound. If HIV 
virologic  rebound is confirmed at the scheduled or unscheduled visit, the blood samples 
from this visit will be used for HIV genotype/phenotype testing. If no resistance to the 
subject’s current ARV regimen is detected, the subject may continue on current ARV 
regim en. 
 
HCV study drug should be continued unless safety events or HCV response based 
stoppi[INVESTIGATOR_762366], as outlined i n Section 3.4 
of the protocol.  
 
For those with chronic HBV infection taking chronic suppressive therapy, if HBV flare 
does occur, monitoring and treatment plan will be discussed with medical monitor on an 
individual basis.  
 
3.5 CONCOMITANT MEDICATIONS  
Concomitant medications taken within 30 days of screening through 30 days  following 
discontinuation of study treatment need to be recorded in the source documents.  
The following medications are prohibited from 2 8 days prior to the Day 0 visit through the e nd 
of treatment:  
 Hematologic stimulating agents (e.g. , erythropoiesis -stimulating agents (ESAs); granulocyte 
colony stimulating factor (GCSF); thrombopoietin (TPO) mimetics)  
 Chronic systemic immunosuppressants including, but not limited to, corticosteroids  
(prednisone equivalent of >10 mg/day for >2 weeks), azathioprine, or monoclonal antibodies 
(e.g., infliximab)  
 Investigational agents or devices for any indication  
 Concomitant use of certain medications or herbal/natural supplements (inhibitors or inducer s 
of drug transporters i.e., P -gp) with study drug(s) may result in pharmacokinetic interactions 
resulting in increases or decreases in exposure of study drug(s).   Examples of representative 
medications which are prohibited from 21 days prior to Day  0 through the end of treatment 
are listed below .  
 Medications for disease conditions excluded from the protocol (e.g., active cancer, 
transplantation) are not listed under this Concomitant Medication section and are disallowed 
in the study.  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 35 of 55 
  Should subjects have a need to initiate treatment with any disallowed concomitant 
medication, the medical monitor must be consulted prior to initiation of the new medication  
  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 36 of 55 
 Table 3-1:  Disallowed and Concomitant Medications to be Used with Caution  
Drug Class  Agents Disallowed  Use with Caution  
Acid Reducing Agentsa  Proton -Pump Inhibitors, H2 -Receptor 
Antagonists, Antacids  
Anticoagulants   Dabigatran Etexilated 
Anticonvulsants b Phenobarbital, Phenytoin, Carbamazepi[INVESTIGATOR_050],  
Oxcarbazepi[INVESTIGATOR_762367] b Rifabutin, Rifapentine, Rifampi[INVESTIGATOR_762368] c Digoxind 
Herbal/Natural 
Supplementsb St. John’s Wort, Echinacea, Milk thistle 
(i.e., silymarin), Chinese herb sho -saiko -to 
(or Xiao -Shai -Hu-Tang)   
HMG -CoA Reductase  
Inhibitorse Rosuvastatin  Pravastatin  
a Proton -pump inhibitors (PPIs) comparable to omeprazole [ADDRESS_1044384] not exceed the equivalent of 40 mg of famotidine twice daily. Antacids that directly neutralize stomach pH (i.e. 
Tums, Maalox) may not be taken within 4 hours (before or after) of SOF/VEL/VOX FDC administration.  
b May result in a decrease in the concentrations of study drugs.  
c May result in symptomatic bradycardia. Mechanism is not currently known. The use of amiodarone  is prohibited from 
60 days prior to  Day-1 through the end of treatment.  
d May result in an increase in the concentration of study drugs and/or concomitant medications  
e Use with study drugs may result in an increase in the concentration of the HMG -CoA Reducta se Inhibitors. Monitor for 
signs and symptoms of muscle weakness or myopathy, including rhabdomyolysis. Pravastatin may be administered with 
SOF/VEL/VOX FDC at a dose that does not exceed pravastatin 40 mg.  
4 STATISTICAL CONSIDER ATIONS  
This study is a single -cente r trial to assess the safety and tolerability of SOF/VEL /VOX . 
4.[ADDRESS_1044385] previously been treated 
with unsuccessful combination DAA -based therapy.   
 
An anticipated sample size of approximately 120 patients will provide a 97% power to detect at 
least an absolute 15% improvement in SVR 12 from the conservative estimate of 70%[ADDRESS_1044386] at a significant level of 0.05 (See Table 4 -1). 
Table 4 -1 Power calculations for observed SVR12 rate compared to Historical rate of 70%  
Ho SVR12  Ha SVR12  Sample Siz e Power  
70% 80% 120 0.641  
70% 85% 120 0.968  
70% 90% 120 >0.999  
70% 95% 120 >0.999  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044387] 
1 adverse event of probability 5% or more.  If the true event probability is 5% or more, there is 
about a 99.8% chance of observing at least 1 such adverse event . Consequently, if no one has a 
given type of AE, we can be confident that its true probability is under 5%. This trial will 
provide preliminary evidence on the safety and efficacy of SOF/ VEL /VOX .  A previous study of 
SOF/ VEL  FDC in subjects with genotype 1 led to a sustained virologic response at Week 12 
(SVR 12) in all participants.  We therefore expect SVR  to 80% or higher.  If the true suppression 
rate is 80%, we will be able to estimate the probability of suppression to within approximately 
±1.96 [(.8)(1 -.8)/120]1/2=.07  (Table 4 -2). For sample sizes shown in row 1, row 2 gives the 
accuracies of the estimates of the proportion o f patients suppressed to below the limit of 
detection (based on a 95% confidence interval).  
Table 4-2:  Sample Size   
 
n=50  n=75  n=100  n=120  
±.11 ±.09 ±.08 ±.[ADDRESS_1044388] adverse event rates of a frequency of 1% and 5% with 63% and 
99% probability, respectively.  
 
Table 4-3:  Advers e Event Probability Table  
 
 Probability of Adverse Event  
 0.01 0.05 0.10 0.15 
N=75  52% 98% >99.9%  >99.9%  
N=100  63% 99% >99.9%  >99.9%  
N=120  70% 99.8 >99.9%  >99.9%  
 
4.1.1 Primary Endpoint  
The primary efficacy endpoint is SVR 12 (HCV RNA <LLOQ 12 weeks after cessation of 
therapy).  
The primary statistical hypothesis for efficacy is that SVR 12 rate is higher than the conservative 
estimate of 70%20.  
 
 Ho: SVR12  = 70%  
 Ha: SVR12 ≠ 70%  
 
The primary analysis will be intention -to-treat, including all enrolled subjects into the study and 
received at least one dose of study drug,  performed after all enrolled subjects have been followed 
through [ADDRESS_1044389] -treatment or discontinued from stud y. 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 38 of 55 
 4.1.2 Secondary Endpoints  
Secondary efficacy endpoints include: HCV RNA  < LLOQ at 4 and 24 weeks after 
discontinuation of therapy (SVR 4 and SVR 24); viral breakthrough; and relapse.  
Descriptive summaries and listings will be provided for additional efficacy ev aluations of the 
proportion of subjects who experience virologic failure and other endpoints of interest including 
ALT normalization, serum HCV RNA actual values, and change from baseline.  
Exploratory analyses may be performed to assess the relationship b etween demographic, baseline  
characteristics, (including baseline viral load, genotype, age, sex, race, ethnicity, 
presence/absence of cirrhosis, baseline ALT level, prior treatment experience, response to 
previous treatment [if applicable], and BMI) and a ntiviral activity (HCV RNA reduction, 
proportion of subjects with HCV RNA <LLOQ at various time points during and following 
discontinuation of all therapy). Predictive factors of antiviral activities may be examined using 
regression type of analysis.  Chang es in HCV specific CD8 responses in patients with cirrhosis 
and not with cirrhosis.  Changes in HCV  specific immune responses in patients treated with 
single (NS5B) DAA versus dual (NS5B + NS5A) versus triple combination DAA (NS5B + 
NS5A + NS3 ) using sampl es from SPARE and this study  
4.1.3 Safety Endpoints  
The primary safety endpoint is any AE leading to permanent discontinuation of study drug(s).  
[IP_ADDRESS]  Other Endpoints of Interest  
Additional efficacy evaluations may include HCV RNA change from Day 0 ; ALT normalization ; 
and viral kinetic parameters.  
4.1.4 Analysis Sets  
[IP_ADDRESS]  Efficacy  
The analysis set for antiviral activity analyses will include subjects who were enrolled into the 
study and received at least one dose of study drug.  
[IP_ADDRESS]  Safety  
The primary analysis set for safety analyse s will include subjects who received at least one dose 
of study drug.  
Safety will be evaluated by [CONTACT_123305], physical examinations , and 
vital signs measurements at various time points during the study, as well as the documenta tion of 
AEs.  
On treatment data will be analyzed and defined as data collected from the first dose of study drug 
through the date of last dose of study drug plus 30 days.   
[IP_ADDRESS]  Pharmacokinetics  
The PK analysis set will include all subjects who are enrolled and have received at least one dose 
of study medication.  The PK analysis set will be used for analyses of general PK.  The intensive 
PK analysis will include the 20 participants who were enrolled in the sub study.  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044390] -baseline categorical efficacy endpoints, if a data point is missing and is 
preceded and  followed in time by [CONTACT_762398], then the missing data point 
will be termed a success; otherwise the data point will be termed a failure.  
Any subject with missing data due to premature discontinuation of the study medication will be 
considered a failure at the time points on, or following, the date of discontinuation. If no HCV 
RNA values are obtained after the last dose of study medication, the subject will be considered a 
treatment failure for the SVR endpoints.  
Where appropriate, s afety data for subjects that did not complete the study will be included in 
summary statistics. For example,  
 If a subject received study medication, the subject will be included in a summary of adverse 
events according to the treatment received; otherwise,  if the subject is not dosed then they 
will be excluded from the summary.  
 If safety laboratory results for a subject are missing for any reason at a time point, the subject 
will be excluded from the calculation of summary statistics for that time point. If  the subject 
is missing a pre -dose value, then the subject will be excluded from the calculation of 
summary statistics for the pre -dose value and the change from pre -dose values.  
Values for missing vital signs data will not be imputed; however, a missing D ay [ADDRESS_1044391] descriptive 
methods by [CONTACT_166884].  
Demographic data will include sex, self -identified race/ethnicity, and age.  
Baseline characteristic data will include body mass index  (BMI) , presence or absence of 
cirrhosis, HCV RNA level (log 10 IU/mL), HCV genotype, and additional endpoints as necessary . 
4.[ADDRESS_1044392] dose of s tudy drug plus 30 days.  
Summaries (number and percentage of subjects) of treatment -emergent adverse events will be 
provided .  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044393] 8 
weeks or at an outside facility (with the exception of safety labs chemistries, hCG, CBC with 
differential, coagulation studies) can be used if within the [ADDRESS_1044394] does 
not need to be done in participants know n to be HIV infected.  Similarly, HBV serologic testing 
does not need to be done in participants known to be chronically HBV infected who are  on 
suppressive therapy.   
 
Serum Chemistry and Hematologic Profiles  
Acute Care Panel, Hepatic Panel, Mineral Panel, and CBCs (with differential) will be performed 
to monitor clinical status, document drug -related benefits and detect potential drug -related 
toxicities. These may be done on screening, d ays 0, 7, 14, and every  scheduled visit thereafter 
through  post-treatment Week 24.  Highly sensitive C -reactive protein may also be done at Days 
0, weeks 1 (optional) , 2, 4, 12 (end of therapy ), as well as post -treatment weeks [ADDRESS_1044395] assay on screening, end of therapy (Week 12), prior to liver biopsy and 
post-treatment Week 24. 
 
Creatine Kinase, Lactate Dehydrogenase, Lipase, Amylase.  
Measured by s tandard assay on screening and Weeks 4 , end of therapy (Week 12) and post-
treatment Week  12. 
 
Alpha Fetoprotein, HCV genotype, Hemoglobin A1C , HIV testing.  
Measured by [CONTACT_83543] s as part of screening.   Hemoglobin A1C will be repeated at Day 0, 
End of  therapy: (Weeks 12), and post -treatment Weeks 12 and 24. 
 
Serum/Urine Pregnancy Test  
Measured by [CONTACT_762399], on Day 0, and then every [ADDRESS_1044396] treatment completion  for women of childbearing potent ial. 
 
SOF/ VEL /VOX  level  
Measured at scheduled study visit continuing through the End of Treatment visit.  Actual date 
and time of PK sample collection  and study drug administration  will be recorded.  
 
HCV RNA Levels  (HCV Viral Loads)  
This will be performed at the following study points: screening; day 0; weeks 1 (optional visit) , 
2, 4, 8; end of therapy (week 12); post treatment weeks 4, 12,  and 24.  
 
HCV Genotype Assay  
This will be performed  at screening if not on file. A result from an outside lab can be used if it 
was completed after documented treatment failure.  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044397]   
This will be performed in HIV coinfected individuals at the following study points: screening, 
day 0, weeks 4, 8, [ADDRESS_1044398]  
This will be performed in HIV coinfected individuals at the following study points: screening, 
week [ADDRESS_1044399]  
This will be performed in chronically HBV -infected individuals at the following study points: 
day 0, on -treatme nt weeks 4, 8, and [ADDRESS_1044400] -treatment weeks 4 and 12.  
 
VK/PK Sub Study  
Subjects will have blood drawn at time points 0, 1, 2, 4, 8, 24 and 72 hours after administration 
of drug to assess drug levels  and HCV viral load levels.   
 
Research tests  
HCV Virol ogic Studies  
Full length HCV genome pyro sequencing may be performed using the protocol as described and 
compared for variability of sequences27. 
 
DNA Methylation Studies  
Promoter methylation status for candidate genes or at a whole genome level using methylation –
specific PCR may be performed on tissue samples28. 
 
rs12979860 (IL28B) Genetic Variant  
IL28B genetic variants have been shown to predict HCV treatment induced clearance29. The 
IL28B assay is a real -time PCR assay that utilizes [ADDRESS_1044401] dose of study drug to determine the time for the resistant virus to return to 
background levels.  
 
Immunophenotypi[INVESTIGATOR_48908] T cells  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044402], CD38, 
Ki67, FoxP3, CTLA4, Tim -3, PD -1 and CD57.  The percentage of cells expressing each and 
multiple markers will be determined by [CONTACT_4133] (BD FACSAria). Data will be  analyzed 
using FlowJo (TreeStar) software.  
 
Determination of HCV specific polyfunctional CD4 and CD8 T cells  
For characterization of HCV specific T cell phenotype and function, peripheral T cells will be 
isolated from PBMCs by [CONTACT_138789] -paque density gradien t separation to be stimulated with pooled 
HCV genotype specific peptides.  For this experiment, we will use HCV 15 -18-mer peptides 
with 11 or 12 amino acid overlaps spanning the entire HCV polyprotein (Mimotopes, Peptide 
Array, HCV), reconstituted in 5% st erile dimethylsulphoxide (DMSO), pooled consecutively 
into twenty -one groups and aliquotted until use. The number of HCV -responsive IFN -γ-
producing PBMC will be quantified by [CONTACT_762400] (BD Biosciences), in which 96 
well ELISPOT plates are coat ed with anti -IFN-γ biotinylated capture antibody and incubated 
overnight at 4°C. Plates will be blocked using lymphocyte medium, and PBMC allowed to rest 
for 6 hours at 37°C.  PBMC will be plated between 250,000 - 400,000 cells per well with either 
phytohae magglutinin (PHA) as a positive control (5 mg/ml), DMSO as a negative control 
(0.05%), or pooled HCV peptides (3 mg/ml/peptide). All cultures will be performed in duplicate. 
After incubating for 12 hours at 37°C, cells will be removed, and plated with stre ptavidin 
detection antibody, enzyme conjugate, and substrate. The plates will then be air dried in the dark 
overnight, and developed spots will be enumerated using an ELISPOT plate reader.  
 
Further testing of HCV responsive T cells will be conducted by [CONTACT_762401]. To 
identify HCV responsive cell populations, carboxyfluoresceinsuccinimidyl ester (CFSE) dilution 
will be utilized. PBMC will be washed and incubated with 2.5mM CFSE (Invitrogen) at 37°C for 
6 minutes, quenched with PBS + 5% fetal c alf serum (FCS), and washed three times with 
lymphocyte medium. PBMC will be incubated at 5x106 in 1.2 mL with either pools of 
overlappi[INVESTIGATOR_762369] (3mg/mL/peptide) or DMSO (1%) and 
NH 4OH (0.7mM) as a vehicle control for a total of 48 hours. Brefeldin A and monensin will be 
added at 36 hours to block the Golgi apparatus and allow intracellular cytokine accumulation. 
Following incubation, PBMC will be harvested and stained with LIVE/DEAD Near -IR 
(Invitrogen) for 30 minutes on  ice. The percentage of live, CFSE+ cells will be assessed by [CONTACT_762402] (FACSAria) and analyzed using FlowJo software (TreeStar) for phenotype and 
function using the antibodies described previously. To assess secreted cytokine production, 100 
μl of supernatant will be collected at 36 hours and frozen at -80°C until used.  Samples will be 
thawed and analyzed for cytokine production using Mesoscale Discovery Human TH1/TH2 10 -
plex ultra -sensitive kit (catalog #K15010C -1) according to manufacturer’s p rotocol. All samples 
will be tested in duplicate.  
 
Determination of T cell defects in liver with mass cytometry using CYTOF  
Liver infiltrating lymphocytes ( LIL) will be isolated from liver biopsy specimen and evaluated 
for markers of immune exhaustion and activation on effector and memory T cell subsets.  
Because we are able to obtain limiting number of lymphocytes from liver biopsies (up  to 1 
million cells per biopsy) it will be critical to use a technology that maximize the spectrum of T 
cell phenotypes v isualized. Although flow cytomtery -based immunophenotypi[INVESTIGATOR_762370]: SEPTEMBER [ADDRESS_1044403] cellular phenotypes and relate them to one another wi thout the 
ability to evaluate simultaneously at many phenotypic markers, functional capacity, and antigen 
specificity in individual cells. Flow cytometry is limited by [CONTACT_762403] 12 –18 
parameters because of overlappi[INVESTIGATOR_762371]. We plan to use a recently developed single -cell mass spectrometric (cytometry by 
[CONTACT_5586]-of-flight or CyTOF) approach in which heavy metal isotopes are used to label antibodies 
and then labeled cells are analyzed by [CONTACT_143011] h throughput mass spectrometry to quantify [ADDRESS_1044404] CD8+ T cell 
subsets, a nearly  combinatorial diversity in the critical liver infiltrating lymphocyte population. 
Phenotypic and functional characterization of liver cells will be done on [ADDRESS_1044405] the samples for levels and exhaustion status of their HCV specific 
polyfunctional T cells. The University of Maryland School of Medicine Cellular Flow Cytometry 
Core Lab will provide technical assistance in design, d ata acquisition and analysis of all CyTOF 
experiments on fee -for-service basis.  
 
Flow cytometry for B cell phenotypi[INVESTIGATOR_007]  
B cell subpopulations will be phenotyped by [CONTACT_762404] (pre -treatment) and at 
the end of treatment and compared with samples from healthy volunteers as controls, matched 
for age and gender. Multicolor flow cytometry analyses will be perform ed on cryopreserved 
PBMC. Lymphocyte counts will be determined by a core facility following standard procedures. 
The frequency of each B cell subpopulation will be determined by [CONTACT_4133]. The 
following fluorochrome -conjugated monoclonal antibodies wi ll be used in the B cell staining 
strategy: V450 anti -CD3 (BD Biosciences, Carlsabad, CA); PerCP -Cy5.5anti -CD19, PE -Cy7 
anti-CD27 (eBioscience, San Diego, CA); FITC anti -CD21 (Beckman Coulter, Brea, 
CA);allophycocyanin (APC) anti -CD10, APC -H7 anti -CD20 (BD  Biosciences, San Jose, CA); 
PE anti -CD95 (BD Biosciences, Carlsabad, CA). Analyses will be performed on a FACSAria 
flow cytometer (BD Biosciences,San Jose, CA) with FlowJo software (TreeStar, Ashland, OR). 
The following B cell subpopulations will be defin ed: immature/transitional, naïve, resting 
memory, tissue -like memory, plasmablast, and activated memory.  
 
Determination of antigen specificity of B cells  
In previous work, we performed immunophenotypi[INVESTIGATOR_31081] B cells, which demonstrated persistence 
of abnorma l phenotype of peripheral B cells in chronic HCV infected  subjects undergoing  
treatment with 3DAAs. In this regard, there was a higher percentage of TLM B cells present in 
the peripheral blood of patients at the end of antiviral therapy. Using samples stor ed from 
patients from previous protocols, we will determine the antibody responses to HCV antigens 
during and after treatment in this study. Ruc -antigen fusions, including HCV core, have been 
previously described. We modified the LIPS technology for simult aneously screening protein 
panels arranged in a [ADDRESS_1044406] produced and stored frozen at−80°C to be used 
to generate an “antigen cell” for eac h protein. After incubation with serum samples, the serum -
Ruc-antigen mixtures from each well of the microtiter plate were transferred to microtiter filter 
plates containing protein A/G beads. Each [ADDRESS_1044407] 
LIPS format for  washing and measuring light units (LU) using a plate luminometer. Luciferase 
immunoprecipi[INVESTIGATOR_762372] -antigens will be 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 44 of 55 
 performed in duplicate as previously described at baseline, weeks 4, 12 and 24 using 50 uL of 
cryopreserved serum per assay. Antibody titers, reported in LU, will be reported as the average 
of two independent experiments, after correction for background LU  values. Changes in antibody 
titer from baseline and absolute antibody titers will be measured in patients undergoing treatment 
and compared.  
 
RNA Seq Analysis.   
We will perform transcriptional analysis of whole blood (Paxgene) and LILs. Illumina RNAseq 
libraries will be prepared with the TruSeq RNA Sample Prep kit (Illumina). Between first and 
second strand cDNA synthesis, the primers and nucleotides will be removed from the samples 
with NucAway spin columns (Ambion). The second strand will be synthesize d with a dNTP mix. 
Adapters containing 6 nucleotide indexes will be ligated to the double -stranded cDNA. After 
adapter ligation, the second strand cDNA will be digested with 2 units of Uracil -N-Glycosylase 
(Applied Biosystems). The DNA will be purified bet ween enzymatic reactions and the size 
selection of the library will be performed with AMPure XT beads (Beckman Coulter Genomics). 
The quantity and size of the libraries were assessed on the LabChip GX (Perkin Elmer) and with 
the Library Quantification Kit for Illumina (Kapa Biosciences)30. Analysis of data, including 
alignment and statistical analysis  
 
6 HAZARDS/DISCOMFORTS/ RISKS  
6.1 DRUGS  
6.1.1 Sofosbuvir  
SOF is an FDA -approved medication for the treatment of HCV.  As per the package  insert, 
common side -effects of SOF therapy include, but are not limited to fatigue , headache , dizziness , 
and nausea . There may be additional side effects of SOF that are not yet known.  SOF has been 
administered to over 10,000 subjects in combination with a DAA, Peg -IFN, and/or RBV in 
[COMPANY_009]’s clinical development  programs as of July 2015.  No clinical safety issues related to SOF 
have been identified to date.  
 
6.1.2 Velpatasvir  
In early studies done on those with HCV using VEL , participants  experienced mild to moderate 
headache (20%), frequent daytime urination (20%), and upper respi[INVESTIGATOR_4416]. Other side 
effects seen less frequently were drowsiness, nausea and dizziness, which were  seen in the same 
frequency as the group taking a placebo.  In healthy volunteers, the following mild side effects 
were seen in more than two participants:  headache, chest pain, feeling hot, constipation, rash 
with itching, and upper respi[INVESTIGATOR_4416] .  One participant had more serious abdominal pain, 
but also had a history of abdominal pain prior to the study.  No significant laboratory  changes 
occurred in either group requiring any type of intervention. There may be ad ditional side effects 
of VEL  that are not yet known.  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 45 of 55 
  
The safety profile of the regimen of SOF 400  mg and VEL  100 mg administered for 12 weeks 
has been established in  approximately 230 subjects enrolled in Phase 2 studies . No clinical safety 
issues specifically related to VEL  or SOF+VEL  have been identified to date.  
 
6.1.[ADDRESS_1044408] received SOF/VEL+ VOX  in the Phase 1, 2, and [ADDRESS_1044409] been no clinical safety issues identified. There is no expectation of significant 
overlappi[INVESTIGATOR_762359], unexpec ted toxicities upon coformulation of SOF/VEL  with VOX  as an 
FDC; data from study GS -US-367-1176 comparing SOF/VEL+ VOX  with SOF/VEL/ VOX  were 
consistent with this. However, a potential risk of the study includes the identification of 
previously undetected adverse effects.  
6.1.[ADDRESS_1044410] reported barrier to resistance among NS3/4A PIs 
and so the anticipated clinical risk of developi[INVESTIGATOR_21395] -resistant mutants with VOX  is anticipated 
to be lower than that associated with first and second generation NS3/4A  PIs Accordingly, there 
was a lack of any viral breakthrough during therapy with VOX  in the 3 -day monotherapy study. 
Mutants generated in vitro to be resistant to VOX remain sensitive to SOF and GS -5816, 
supporting the clinical use of VOX  in combination wi th other classes of HCV inhibitors. Lastly, 
this risk is balanced by [CONTACT_762385]/VEL /VOX  in Phase [ADDRESS_1044411] future therapeutic options. However all efforts will 
be made to manage the development of class specific mutations that could lead to cross 
resistance to other NS5B , NS5A , and NS3  inhibitors.  
  
6.2 PROCEDURES  
6.2.1 Phlebotomy  
The primary risks of phlebotomy inclu de occasional bleeding or bruising of the skin at the site of 
needle puncture, and the sensation of transient lightheadedness or rarely, fainting  and infection . 
The amount of blood drawn will be within the limits allowed for adult subjects (450 ml over 6 
weeks) .  
6.2.2 Electrocardiogram  
This will be performed at screening for all participants and if medically indicated while on study.  
Subjects may experience itching, redness or irritation at the site of the electrodes.  
6.2.3 Liver Biopsy  
Liver biopsies performed within  36 months prior to Day 0, either the University of Maryland  or 
outside institutions, will be acceptable as inclusion criteria based upon the written pathology 
report.  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044412] any major 
late manifestations of complications associated with liver biopsy.  
 
 
7 BENEFITS/COMPENSATIO N/ALTERNATIVES  
7.[ADDRESS_1044413] the 
PI. Short -term medical care will be provided, as needed, for such injury. There is no pro vision 
for long -term free medical care or for monetary compensation from any injury from the 
physicians conducting this study, from the Institute of Human Virology, University of Maryland 
or [COMPANY_009] Sciences  
 
7.2 ALTERNATIVES  
Subjects can receive hepatitis C tr eatment through their private physician or decide not to be 
treated at this time.   
 
7.3 COMPENSATION  
Subjects will receive remuneration for the immediate costs associated with their study -related 
expenses like travel expenses, lodging, etc. Subjects will also  receive financial compensation for 
the additional time associated with study related procedures such as research blood draws for the 
PK/VK sub study and liver biopsy. Subjects will be financially compen sated for the 
inconvenience of the procedures necessa ry to obtain the samples. The compensation will be as 
follows:  
 Liver Biopsy  with research specimens :  $250  cash per biopsy (maximum of 2)  
 VK sub study:  $200  cash after completion of all time points.  
 Scheduled Study Visits: $[ADDRESS_1044414] for lab visits and $[ADDRESS_1044415]  for study visits.  
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 47 of 55 
 8 ADVERSE EVENTS AND TO XICITY MANAGEMENT  
8.1 DEFINITIONS  
Adverse Event (AE):  An adverse event is a ny untoward or unfavorable medical occurrence in a 
human subject, including any abnormal sign (e.g. abnormal physical exam or laboratory finding), 
symptom, or disease, temporally associated with the subject’s participation in the research, 
whether or not considered related to the research . 
 
Serious Adverse Event (SAE) :  
A Serious Adverse Event is a n AE that results in one or more of the following outcomes:  
 
 death  
 a life -threatening (i.e., an immediate threat to life) event  
 an inpatient hospi[INVESTIGATOR_1324] ; 
 a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions  
 a congenital anomaly/birth defect  
 a medically important event*  
 
* Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other sit uations, such as important medical events that may not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_762373].  
 
Unexpected Adve rse Event:  An AE is unexpected if it is not listed in the Investigator ’s 
Brochure or Package Insert (for marketed products) or is not listed at the specificity or severity 
that has been observed.  It is the responsibility of the IND Sponsor to make this d etermination.  
 
Serious and Unexpected Suspected Adverse Reaction (S[LOCATION_003]R):  A S[LOCATION_003]R is a Suspected 
Adverse Reaction that is both Serious and Unexpected.   
 
Unanticipated Problem That Is Not An Adverse Event (UPnonAE):  An unanticipated 
problem that does not fit the definition of an adverse event, but which may, in the opi[INVESTIGATOR_1070], involve risk to the subject, affect others in the research study or significantly impact 
the integrity of the research data.  Such events would be considered a non -serious UP.  For 
example, we will report occurrences of breaches of confidentiality, accidental destruction of 
study records, or unaccounted -for study drug . 
 
Protocol Deviation:  Any change, divergence, or departure from the IRB approved study 
procedures in a research protocol .  Protocol deviations are designated as serious or non -serious 
and further characterized as : 
 
1. Those that occur because a member of the research team deviates from the protocol.  
2. Those that are identified before they occur, but cannot be prevented.  
3. Those that are discovered after they occur  
 
Non-compliance:  The failure to comply with applicable IRB requirements, or regulatory 
requirements for the protection of human subjects. Non -compliance is further characterized as  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 48 of 55 
 1. Serious: Non -complian ce that  
a. Increases risks, or causes harm, to participants  
b. Decreases potential benefits to participants  
c. Compromises the integrity of the UMD IRB  
d. Invalidates the study data  
2. Continuing: Non -compliance that is recurring  
3. Minor: Non -compliance that, is neither se rious nor continuing.  
 
8.[ADDRESS_1044416] be recorded as an AE or SAE if 
applicable.  
 
Laboratory assessments that are associated with signs and/or symptoms must be recorded as an 
AE or SAE if they meet the definition.  
 
All AEs occurring from the time of ingesting one dose of the medications through the end of 
study will be documented, recorded, and reported.   The Investigator will evaluate all AEs with 
respect to Seriousness  (criteria listed above), Severity  (intensity or grade), and Causality  
(relationsh ip to study agent and relationship to research) according to the following guidelines.  
8.2.1 Severity Grading  
The investigator will grade the s everity of each AE according to the “ Division Of A IDS Table 
For Grading The Severity Of Adult And Pediatric Adverse Events” (Version 1.0, December, 
2004; Clarification August 20 09), which can be found at: http://rsc.tech -
res.com/document/safetyandpharmacovigilance/table_for_grading_severity_of_adult_pediatric_a
dverse_eve nts.pdf   
  
Please note that changes in hemoglobin will be graded only by [CONTACT_762405].  
Adverse Events not found in the Toxicity Table will be assessed for severity and classified into 
one of the categori es below:  
 Grade 1 (Mild) : Event requires minimal or no treatment and do not interfere with the 
participant’s daily activities.  
 Grade 2 (Moderate) : Event results in a low level of inconvenience or concern with the 
therapeutic measures.  Moderate events may cause some interference with functioning.  
 Grade 3 (Severe) : Event interrupts a subject’s usual daily activity or functioning and may 
require systemic drug therapy or other treatment.  Severe events are usually incapacitating.  
 Grade 4 (Potentially Life thre atening) :  Events causing inability to perform basic self -
care functions OR Medical or operative intervention indicated to prevent permanent 
impairment, persistent disability, or death.  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 49 of 55 
  Grade 5 (Death)  
8.2.2 Causality   
Causality (likelihood that the event is rel ated to the study agent) will be assessed from 
the time study dosing begins until [ADDRESS_1044417] dose considering the 
factors listed under the following categories:  
 
Definitely Related     
 reasonable temporal relationship  
 follows a known response pattern  
 clear evidence to suggest a causal relationship  
 there is no alternative etiology  
 
Probably Related   
 reasonable temporal relationship  
 follows a suspected response pattern (based on similar agents)  
 no evidence of a more likely alternative et iology  
 
Possibly Related   
 reasonable temporal relationship  
 little evidence for a more likely alternative etiology  
 
Unlikely Related   
 does not have a reasonable temporal relationship  
OR 
 good evidence for a more likely alternative etiology  
 
Not Related   
 does not have a temporal relationship           
OR 
 definitely due to an alternative etiology  
 
Note:  Other factors (e.g., dechallenge, rechallenge) should also be considered for each 
causality category when appropriate. Causality assessment is based on avai lable 
information at the time of the assessment of the AE. The Investigator may revise the 
causality assessment as additional information becomes available.  
 
8.3 SAFETY OVERSIGHT  
Safety oversight will be conducted according to the Safety Monitoring Plan (see b elow) in a 
collaboration between the  Principal Investigator  (PI), lead Study Coordinator (SC)  and the 
independent Medical Monitor .  
 
8.3.1 Medical Monitor  
An independent Medical Monitor  (MM) has been appointed for oversight of safety in this 
clinical study. If at any point in the trial halting rules are met, the study team (PI [INVESTIGATOR_762374]) will 
arrange a teleconference so that the event can be reviewed and the discussion documented. At the 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 50 of 55 
 end of each MM review meeting, the MM will be asked to provide a formal recomme ndation as 
to whether or not the protocol should be halted. A written summary of each MM review meeting 
will be provided to the MM and appropriate individuals.   Participants on the MM teleconferences 
will include the MM, the PI [INVESTIGATOR_762375] m embers.  
 
8.4 SAFETY MONITORING PLAN  
Ongoing Safety Monitoring by [CONTACT_519292]:  Cumulative safety data will be monitored by [CONTACT_58860] (PI  [INVESTIGATOR_762374]).  Upon recognition of any safety concerns, a teleconference may be held 
with the MM to discuss the concern.  The PI [INVESTIGATOR_762376] (CSO)  when enrollment begins and will provide verification of safety assessments to the 
MM and CSO.  The ISM will review the viral kinetic, pharmacokinetic and resistance data to 
advise regarding continued study enrollment. The study team in collaboration with the study 
sponsor will then make a determination about whether the study enrollment needs to shut down .  
 
Patient safety will be monitored by [CONTACT_978] [INVESTIGATOR_36749]. Patient clinical data, safety data and 
virologic response will be monitored at weekly (or less frequently , as indicated by [CONTACT_762406]) meetings by [CONTACT_762407] a summary report of these reviews will be retained as 
part of the study records . A complete evaluation of safety and efficacy data will be obtained 
when the first 20 patients complete 12 weeks of therapy. Thereafter, safety and data analysis will 
be performed every 12 weeks through completion of the study.  
Additionally, the PI [INVESTIGATOR_762377].  
 
8.5 SPECIFIC STUDY  HALTING CRITERIA  
8.5.1 Criteria to Pause Enrollment  
 Study will be paused  and the MM will be asked to review the data if 1: 3 participants 
experience virologic or therapeutic treatment failure while receiving treatment (see Dose 
Modificatio n 3.4.1  and Treatment Failure  Sections 3.4.2 ) 
 Dosing will be discontinued if 3 or more participants develop a similar r elated Grade 4 
toxicity (excluding neutropenia, anemia, anorexia, weight loss and ALT and AST 
elevations). Further do sing will require review and approval after discussion with the 
MM.   Grade [ADDRESS_1044418] discontinuation.    
 Enrollment will also be halted if the PI [INVESTIGATOR_762378].  
 
8.6 INVESTIGATOR REPORTING RESPONSIBILITIES  
8.6.1 Adverse Events  
Line listings, frequency tables, and other summary AE data will be submitted to the IND 
Sponsor when needed for periodic safety assessments, review of IND annual reports, review of 
IND safety reports, and preparation of final study reports.  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 51 of 55 
 8.6.2 Serious Adverse Events  
Any SAE will be reported to the IRB per institutional guidelines. SAEs ( regardless of 
relatio nship ) must be reported to [COMPANY_009] Drug Safety & Public Health (DSPH)  Office  within [ADDRESS_1044419] becoming aware of the event. Reporting any unexpected  fatal or life -
threatening suspected  adverse reactions to the Division of Antiviral Agents at the FDA no later 
than 7 calendar days after initial receipt of the information. Safety reporting to the FDA will be 
done within the reporting requirement under 21 CFR 312.32  
8.6.3 [COMPANY_009] Safety Data Repor ting 
The [COMPANY_009] DSPH will be notified via email ([EMAIL_201]) of any potential safety 
issues or any protocol amendments or changes to the informed con sent form arising from a 
safety concern associated with any [COMPANY_009] product within fifteen calend ar days of first becoming 
aware of such event. Except for periodic safety reports, copi[INVESTIGATOR_762379], as well as any correspondence with such 
authorities will be provided to [COMPANY_009].  
 
Upon completion of the study, a listing of all safety information that has been sent to [COMPANY_009] 
during the study will be sent to [COMPANY_009] at standards.&[EMAIL_14563] . At a minimum 
the listing must  contain protocol number, patient ID number, case reference number , [COMPANY_009] 
product and event term   
 
8.[ADDRESS_1044420]  as outlined above , information regarding AEs will be elicited by 
[CONTACT_4524] : 
 immediately documented  in the subject’s medical record/ source document. So urce 
documents will include: case report forms (CRFs), progress notes, laboratory reports, 
consult notes, phone call summaries, survey tools and data collection tools. Source 
documents will be reviewed in a timely manner by [CONTACT_5051]. The onset dat e, the 
end date, the severity of each reportable event, and the Investigator’s judgment of the 
AEs relationship to SOF, VEL  and VOX  will also be recorded.  
8.8 FOLLOW -UP OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
Adverse events that occur following initiation  of investigational agent on day 0  will be followed 
at a minimum until  a final outcome is known  (resolution of the AE or a return to baseline 
laboratory  value) or until the end of the study follow -up period (Week 60) .  
SAEs that occur after the study follo w-up period that are reported to and are assessed by [CONTACT_70563], probably, or definitely related must be reported to the CSO  and MM , 
as described above . 
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044421] of the protocol will not be reported to the IRB unless they 
occur at a rate greater than anticipated by [CONTACT_3476]. Expected adverse events will not be 
reported to the IR B unless they occur at a rate greater than that known to occur in Hepatitis C. If 
the rate of these events exceeds the rate expected by [CONTACT_3476], the events will be classified 
and reported as though they are unanticipated problems. Deaths related to the natural history of 
hepatitis C will be reported at the time of continuing review.  
8.9.3 Annual Reporting to the IRB  
The following items will be reported to the IRB in summary at the time of continuing Review:  
 Serious and non -serious  unanticipated problems  
 Expected serious adverse events that are possibly, probably, or definitely related to the 
research  
 Serious adverse events that are not related to the research  
 All adverse events  except expected AEs and deaths granted a waiver of reporting.  
 Serious, continuing, and minor non -compliance  
 Serious and Non -serious protocol deviations  which in the opi[INVESTIGATOR_762380]  
 Any trends or events which in the opi[INVESTIGATOR_762381]  
 
 
8.6.[ADDRESS_1044422] be stopped 
immediately.  The participant will be advised to notify her obstetrician of study agent exposure.   
 
Pregnancy outcome data (e.g., delivery outcome, spontaneous, or elective termination of the 
pregnancy, presence of absence of birth defects, congenital abnormalities, or other 
complications) will be reported to the MM and CSO within 3 business days of the site’s 
awareness on a protocol -specified form.   
 
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044423] KEEPI[INVESTIGATOR_1645]  
9.1 DATA HANDLING  
All research data and results will be recorded using data collection forms. Source documents will  
support the data collected and  will include , but not  limited to;  clinical findings and observations, 
laboratory and test data , hospi[INVESTIGATOR_38109], physician or office charts, physician or  nursing 
notes, recorded data from automated instruments, x -rays, etc. Research data will be entered into a 
secure electronic database   
 
9.[ADDRESS_1044424] RETENTIO N 
The investigator is responsible for retaining all essential documents listed in the ICH Good 
Clinical Practice Guideline.  All essential documentation for all study subjects is to be 
maintained by [CONTACT_83196] a secure storage facility for a minimum of 5 years.  The FDA 
requires study records to be retained for up to 2 years after marketing a pproval or disapproval 
(21 CFR 312.62), or until at least [ADDRESS_1044425] elapsed since the formal discontinuation of 
clinical development of the investigational agent for a specific indication. These records are 
also to be maintained in compliance with IRB/E C, state, and federal medical records retention 
requirements, whichever is longest. All stored records are to be kept confidential to the extent 
required by [CONTACT_1032], state, and local law.  
 
  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER [ADDRESS_1044426]. Global epi[INVESTIGATOR_187791] C virus infection: new estimates of age -specific antibody to HCV seroprevalence. 
Hepatology  2013; 57(4): 1333 -42. 
2. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the 
[LOCATION_002], National Health and Nutrition Examination Survey 2003 to 2010. Annals of 
internal medicine  2014; 160(5): 293 -300. 
3. Kim WR. The burden of hepatitis C in the [LOCATION_002]. Hepatology  2002; 36([ADDRESS_1044427] 
1): S30 -4. 
4. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence -
based approach. Aliment Pharmacol Ther  2014; 39(5): 518 -31. 
5. Mahajan R, Xing J, Liu SJ, et al. Mortality amon g persons in care with hepatitis C virus 
infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006 -2010. Clinical infectious diseases 
: an official publication of the Infectious Diseases Society of America  2014; 58(8): 1055 -61. 
6. Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics 
of decedents with viral hepatitis, [LOCATION_002], 2010. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America  2014; 58(1): 40 -9. 
7. Naggie S, Pate l K, McHutchison J. Hepatitis C virus directly acting antivirals: current 
developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother  2010; 
65(10): [ADDRESS_1044428]  interferon 
alfa-2b, plus ribavirin, for chronic hepatitis C in HIV -infected patients: a randomized controlled 
trial. Jama  2004; 292(23): 2839 -48. 
9. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa -2a (40 kd) and 
ribavirin for black Am erican patients with chronic HCV genotype 1. Hepatology  2004; 39(6): 
[ADDRESS_1044429], et al. Ledipasvir and sofosbuvir for previously treated 
HCV genotype 1 infection. The New England journal of medicine  2014; 370(16): 1483 -93. 
11. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV 
genotype 1 infection. The New England journal of medicine  2014; 370(20): 1889 -98. 
12. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT -450/r -ombitasvir 
and dasa buvir with ribavirin. The New England journal of medicine  2014; 370(17): 1594 -603. 
13. Ferenci P, Bernstein D, Lalezari J, et al. ABT -450/r -ombitasvir and dasabuvir with or 
without ribavirin for HCV. The New England journal of medicine  2014; 370(21): 1983 -92. 
14. Poordad F, Hezode C, Trinh R, et al. ABT -450/r -ombitasvir and dasabuvir with ribavirin 
for hepatitis C with cirrhosis. The New England journal of medicine  2014; 370(21): 1973 -82. 
15. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with A BT-450/r -
ombitasvir and dasabuvir with ribavirin. The New England journal of medicine  2014; 370(17): 
1604 -14. 
16. Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir -sofosbuvir with or 
without ribavirin to treat patients with HCV genotype 1 infec tion and cirrhosis non -responsive to 
previous protease -inhibitor therapy: a randomised, double -blind, phase 2 trial (SIRIUS). Lancet 
Infect Dis  2015; 15(4): 397 -404. 
17. Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbu vir 
with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: 
Analysis of phase III ION trials. Hepatology  2015.  
RESOLVE PROTOCOL    PROTOCOL DATE: SEPTEMBER 11 , 2017  
Page 55 of 55 
 18. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 
1 in patients wi th unfavorable treatment characteristics: a randomized clinical trial. Jama  2013; 
310(8): 804 -11. 
19. Wilson EM, Kattakuzhy S, Sims Z, et al. High efficacy of retreatment with ledipasvir and 
sofosbuvir in HCV patients who failed initial short course therap y with combination DAA 
regimens (NIH SYNERGY trial). J Hepatology  2015; 62(S2): S267 -S8. 
20. Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of 
ledipasvir/sofosbuvir -based regimens with ledipasvir/sofosbuvir for 24 weeks  J Hepatology  
2015; 62(S2): S192.  
21. Osinusi A, Kohli A, Marti MM, et al. Re -treatment of Chronic Hepatitis C Virus 
Genotype 1 Infection After Relapse: An Open -Label Pi[INVESTIGATOR_16116]. Annals of internal medicine  
2014; 161(9): 634 -8. 
22. Kirby B, Yang J, Yang C , et al. Evaluation of the pan -genotypic HCV NS3/4A protease 
inhibitor GS -9857 in healthy volunteers. J Hepatology  2015; 62(S2): S663.  
23. Rodriguez -Torres M, Glass S, Hill J, et al. The pan -genotypic NS3/4A protease inhibitor 
GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 
4 in a 3 -day monotherapy study. J Hepatology  2015; 62(S2): S682.  
24. Taylor J, Appleby T, Barasaukas O, et al. Preclinical profile of the pan -genotypic HCV 
NS3/4A protease inhibitor GS -9857. J Hepatology  2015; 62(S2): S681.  
25. Gane E, Hyland RH, Ying Y, et al. Safety and efficacy of short -duration treatment with 
GS-9857 comb ined with sofosbuvir/GS -5816 in treatment -naïve and DAA -experienced genotype 
1 patients with and without cirrhosis. J Hepatology  2015; 62(S2): S264.  
26. Taylor JG, Appleby T, Barauskas O, et al. Preclinical Profile of the Pangenotypic HCV 
NS3/4A Protease I nhibitor GS -9857 [Poster P0899].  European Association for the Study of the 
Liver (EASL) 50th International Liver Congress; 2015 22 -26 April; Vienna, Austria; 2015.  
27. Liu Z, Netski DM, Mao Q, et al. Accurate representation of the hepatitis C virus 
quasis pecies in 5.2 -kilobase amplicons. J Clin Microbiol  2004; 42(9): 4223 -9. 
28. Kristensen LS, Hansen LL. PCR -based methods for detecting single -locus DNA 
methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clinical 
chemistry  2009; 55(8): 1471 -83. 
29. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C 
treatment -induced viral clearance. Nature  2009; 461(7262): 399 -401. 
30. Parkhomchuk D, Borodina T, Amstislavskiy V, et al. Transcriptome analysis by [CONTACT_762408] -
specific sequencing of complementary DNA. Nucleic acids research  2009; 37(18): e123.  
31.  Lawitz E, Reau N, Hinestorsa F, et al. Efficacy of Sofosbuvir, Velpatasvir, and GS -9857 
in Patients with Genotye 1 Hepatitis C Virus Infection in an Open -Label, Phase 2 Trial. 
Gastroenterology 2016; IN PRESS  
32.  Gane EJ, Schwabe C, Hyland R.H, et al . Efficacy of Combination of Sofosbuvi r, 
Velpatasvir, and NS3/4A Protease Inhibitor GS -9857 in Treatment -Naïve or Previously 
Treated Patients with Hepatitis C Virus Genotype 1 or 3 Infections. Gastroenterology 2016; 
151(3); 448 -456. 
. 